{"content":"<li class=\"n-box-item date-title\" data-end=\"1534823999\" data-start=\"1534737600\" data-txt=\"Monday, December 23, 2019\">Monday, August 20, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3384326\" data-ts=\"1534801879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APPN\" target=\"_blank\">APPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384326-appianminus-3_4-after-2m-share-registration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Appian -3.4% after 2M-share registration</a></h4><ul>   <li>Appian (NASDAQ:<a href='https://seekingalpha.com/symbol/APPN' title='Appian Corp.'>APPN</a>) is <font color='red'>down 3.4%</font> after <a href=\"https://seekingalpha.com/filing/4144264\" target=\"_blank\">registering to offer 2M shares</a>.</li>    <li>The company is offering 1.675M on its behalf, and selling stockholders affiliated with Chairman Matthew Calkins, founder Robert Kramer and others are offering 325,000 shares</li>    <li>The offering comes via Barclays.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384326\" data-linked=\"Appian -3.4% after 2M-share registration\" data-tweet=\"$APPN - Appian -3.4% after 2M-share registration https://seekingalpha.com/news/3384326-appianminus-3_4-after-2m-share-registration?source=tweet\" data-url=\"https://seekingalpha.com/news/3384326-appianminus-3_4-after-2m-share-registration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384320\" data-ts=\"1534801474\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NDSN\" target=\"_blank\">NDSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384320-nordsonminus-7_2-amid-revenue-slowdown\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nordson -7.2% amid revenue slowdown</a></h4><ul>   <li>Nordson (NASDAQ:<a href='https://seekingalpha.com/symbol/NDSN' title='Nordson Corporation'>NDSN</a>) is <font color='red'>off 7.2%</font> after hours following a <a href=\"https://seekingalpha.com/news/3384285-nordson-eps-line-misses-revenue\" target=\"_blank\">fiscal Q3 report</a> where revenues were just short of expectations and guidance looked to be on the lighter side for the current quarter.</li>    <li>Gains in adhesive dispensing were offset by a letdown in advanced technology systems, where the company saw an 11% decrease in organic volume.</li>    <li>EPS was in line; EBITDA of $163.4M was down 8.9% Y/Y.</li>    <li>Backlog was about $428M, up 16% (up 15% organically and 1% due to acquisitions).</li>     <li>Sales by segment: Adhesive dispensing systems, $244.7M (up 4.9%); Advanced technology systems, $266.6M (down 8.2%); Industrial coating systems, $69.9M (up 6.5%).</li>    <li>Sales by geography: United States, $191.5M (up 4.7%); Americas, $38.9M (down 6.5%); Europe, $150.7M (up 12.6%); Japan, $28.4M (down 31.6%); Asia Pacific, $171.7M (down 9.4%).</li>    <li>For Q4 it expects sales of flat to down 4%; that's based on organic volume between +1% and -3%, 1% growth from first-year effect of acquisitions, and -2% due to currency translation. At the midpoint, that makes for operating margin of 22%.</li>    <li>It's forecasting GAAP EPS of $1.38-$1.54, and EBITDA of $149M.</li>    <li><a href=\"http://www.nordson.com/investors\" target=\"_blank\">Conference call</a> to come tomorrow at 8:30 a.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17249319-nordson-corporation-reports-fiscal-year-2018-third-quarter-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3384320\" data-linked=\"Nordson -7.2% amid revenue slowdown\" data-tweet=\"$NDSN - Nordson -7.2% amid revenue slowdown https://seekingalpha.com/news/3384320-nordsonminus-7_2-amid-revenue-slowdown?source=tweet\" data-url=\"https://seekingalpha.com/news/3384320-nordsonminus-7_2-amid-revenue-slowdown\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384317\" data-ts=\"1534801328\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FN\" target=\"_blank\">FN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384317-after-hours-gainers-losers-08-20-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (08/20/2018)</a></h4><ul><li><b>Top Gainers:</b> <a href='https://seekingalpha.com/symbol/FN' title='Fabrinet'>FN</a> <font color='green'>+6.6%</font>. <a href='https://seekingalpha.com/symbol/SENS' title='Senseonics Holdings'>SENS</a>&nbsp;<font color='green'>+3.3%.</font>&nbsp;<a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a>&nbsp;<font color='green'>+3.0%</font>.&nbsp;<a href='https://seekingalpha.com/symbol/CYH' title='Community Health Systems, Inc.'>CYH</a> <font color='green'>+2.9%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a>&nbsp;<font color='green'>+2.1%</font>.</li><li><b>Top Losers:&nbsp;</b><a href='https://seekingalpha.com/symbol/NDSN' title='Nordson Corporation'>NDSN</a> <font color='red'>-7.1%</font>.&nbsp;<a href='https://seekingalpha.com/symbol/TEDU' title='Tarena International, Inc.'>TEDU</a>&nbsp;<font color='red'>-1.9%</font>.&nbsp;<a href='https://seekingalpha.com/symbol/YPF' title='YPF Sociedad Anonima'>YPF</a> <font color='red'>-1.6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384317\" data-linked=\"After Hours Gainers / Losers (08/20/2018)\" data-tweet=\"$FN $FN $SENS - After Hours Gainers / Losers (08/20/2018) https://seekingalpha.com/news/3384317-after-hours-gainers-losers-08-20-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3384317-after-hours-gainers-losers-08-20-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384314\" data-ts=\"1534800452\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VTL\" target=\"_blank\">VTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384314-vital-therapiesplus-2_8-cantor-starts-overweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vital Therapies +2.8% as Cantor starts at Overweight</a></h4><ul>   <li>Biotech firm Vital Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/VTL' title='Vital Therapies, Inc.'>VTL</a>) is <font color='green'>up 2.8%</font> in light aftermarket trading after Cantor Fitzgerald initiated coverage at Overweight.</li>    <li>Analyst William Tanner has a price target of $18, implying 100% upside after the stock closed at $9 today.</li>    <li>Shares are <font color='green'>up 51.3%</font> in 2018, and have <font color='green'>gained 216%</font> over the past 12 months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384314\" data-linked=\"Vital Therapies +2.8% as Cantor starts at Overweight\" data-tweet=\"$VTL $IMUX - Vital Therapies +2.8% as Cantor starts at Overweight https://seekingalpha.com/news/3384314-vital-therapiesplus-2_8-cantor-starts-overweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3384314-vital-therapiesplus-2_8-cantor-starts-overweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384297\" data-ts=\"1534798885\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SITO\" target=\"_blank\">SITO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384297-sito-mobileminus-3_5-q2-revenue-declines-and-misses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sito Mobile -3.5% as Q2 revenue declines and misses</a></h4><ul>   <li>Sito Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/SITO' title='SITO Mobile, Ltd.'>SITO</a>) is <font color='red'>off 3.5%</font> after hours in very light trading after <a href=\"https://seekingalpha.com/news/3384283-sito-mobile-misses-revenue\" target=\"_blank\">Q2 earnings</a> missed expectations.</li>    <li>The company had <a href=\"https://seekingalpha.com/news/3363383-sito-mobile-minus-15-percent-new-q2-revenue-guidance\" target=\"_blank\">warned on revenues</a> in June, trimming expectations to $8M-$9M vs. Q1's $11.1M. Q2 revenues did come in down 22% to $8.43M.</li>    <li>Operating loss grew to $6.1M from a year-ago loss of $2.8M, mainly due to higher expenses from its stock incentive plan, expanding the sales force and customer management team, and increased marketing.</li>    <li>Net loss widened and EBITDA swung to a loss, of $3.6M (vs. a year-ago gain of $1M).</li>    <li>Cash used in operations was $6.1M, inclusive of annual year-end bonuses.</li>    <li>Cash and equivalents came to $6.6M, up from $3.6M as of Dec. 31.</li>    <li><a href=\"https://seekingalpha.com/pr/17249301-sito-mobile-reports-second-quarter-2018-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3384297\" data-linked=\"Sito Mobile -3.5% as Q2 revenue declines and misses\" data-tweet=\"$SITO - Sito Mobile -3.5% as Q2 revenue declines and misses https://seekingalpha.com/news/3384297-sito-mobileminus-3_5-q2-revenue-declines-and-misses?source=tweet\" data-url=\"https://seekingalpha.com/news/3384297-sito-mobileminus-3_5-q2-revenue-declines-and-misses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384288\" data-ts=\"1534797791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FN\" target=\"_blank\">FN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384288-fabrinetplus-6_9-after-q4-beat-strong-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fabrinet +6.9% after Q4 beat, strong guidance</a></h4><ul>   <li>Fabrinet (NYSE:<a href='https://seekingalpha.com/symbol/FN' title='Fabrinet'>FN</a>) has <font color='green'>gained 6.9%</font> after hours following <a href=\"https://seekingalpha.com/news/3384278-fabrinet-beats-0_06-beats-revenue\" target=\"_blank\">fiscal Q4 earnings</a> that topped expectations and contained solid profit guidance for the current quarter.</li>    <li>Net income dipped by about 6.4% on revenues that declined 6.8%.</li>    <li>But revenue was up sequentially on modest growth in optical communications products and \"strong growth\" in non-optical products, notes CEO Seamus Grady.</li>    <li>&ldquo;On a personal note, at my request, our board of directors has initiated a CFO succession plan,\" says Chief Financial Officer Toh-Seng Ng. \"We have retained an executive search firm to assist in identifying and evaluating candidates, and there is no set timeline for this process.&rdquo;</li>    <li>For Q1, it's guiding to revenues of $347M-$355M (vs. consensus for $348.2M) and EPS of $0.80-$0.83 (above expectations for $0.79).</li>    <li><a href=\"https://edge.media-server.com/m6/p/6w9kpjkj\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17249291-fabrinet-announces-fourth-quarter-fiscal-year-2018-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3384288\" data-linked=\"Fabrinet +6.9% after Q4 beat, strong guidance\" data-tweet=\"$FN - Fabrinet +6.9% after Q4 beat, strong guidance https://seekingalpha.com/news/3384288-fabrinetplus-6_9-after-q4-beat-strong-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3384288-fabrinetplus-6_9-after-q4-beat-strong-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384278\" data-ts=\"1534796229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FN\" target=\"_blank\">FN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384278-fabrinet-beats-0_06-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fabrinet beats by $0.06, beats on revenue</a></h4><ul><li>Fabrinet (NYSE:<a href='https://seekingalpha.com/symbol/FN' title='Fabrinet'>FN</a>): Q4 Non-GAAP EPS of $0.81 <span style=\"color:green\">beats by $0.06</span>; GAAP EPS of $0.60.</li><li>Revenue of $345.33M (-6.8% Y/Y) <font color='green'>beats by $7.21M</font>.</li><li>Shares <font color='green'>+5%</font>.</li><li><a href='https://seekingalpha.com/pr/17249291-fabrinet-announces-fourth-quarter-fiscal-year-2018-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3384278\" data-linked=\"Fabrinet beats by $0.06, beats on revenue\" data-tweet=\"$FN - Fabrinet beats by $0.06, beats on revenue https://seekingalpha.com/news/3384278-fabrinet-beats-0_06-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3384278-fabrinet-beats-0_06-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384268\" data-ts=\"1534795780\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGRP\" target=\"_blank\">SGRP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384268-spar-reports-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SPAR reports Q2 results</a></h4><ul><li>SPAR (NASDAQ:<a href='https://seekingalpha.com/symbol/SGRP' title='SPAR Group, Inc.'>SGRP</a>): Q2 GAAP EPS of -$0.09.</li><li>Revenue of $59.22M (+38.6% Y/Y)</li><li>Shares <font color='green'>+4.58%</font>.</li><li><a href='https://seekingalpha.com/pr/17249268-spar-group-announces-financial-results-second-quarter-ended-june-30-2018'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3384268\" data-linked=\"SPAR reports Q2 results\" data-tweet=\"$SGRP - SPAR reports Q2 results https://seekingalpha.com/news/3384268-spar-reports-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3384268-spar-reports-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384255\" data-ts=\"1534794262\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVSI\" target=\"_blank\">CVSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384255-cv-sciences-down-26-on-bearish-citron-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CV Sciences down 26% on bearish Citron report</a></h4><ul><li>Cannabidiol player CV Sciences (<a href='https://seekingalpha.com/symbol/CVSI' title='CV Sciences, Inc.'>OTCQB:CVSI</a> <font color='red'>-25.6%</font>) slumps on more than a 10x surge in volume on the heels of a bearish <a href=\"https://twitter.com/CitronResearch/status/1031592091543982081/photo/1?ref_src=twsrc%5Etfw%7Ctwcamp%5Eembeddedtimeline%7Ctwterm%5Eprofile%3Acitronresearch&amp;ref_url=https%3A%2F%2Fcitronresearch.com%2F\" target=\"_blank\">tweet </a>from Citron Research claiming the bull thesis is based on patents that have never been issued.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384255\" data-linked=\"CV Sciences down 26% on bearish Citron report\" data-tweet=\"$CVSI - CV Sciences down 26% on bearish Citron report https://seekingalpha.com/news/3384255-cv-sciences-down-26-on-bearish-citron-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3384255-cv-sciences-down-26-on-bearish-citron-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>64&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384253\" data-ts=\"1534793969\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRK\" target=\"_blank\">MRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384253-fda-oks-mercks-keytruda-for-first-line-lung-cancer-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Merck&#39;s Keytruda for first-line lung cancer; shares up 2%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17249274-fda-approves-expanded-label-merck-s-keytruda-pembrolizumab-combination-pemetrexed-alimta\" target=\"_blank\">approves </a>Merck's (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='green'>+1.5%</font>) KEYTRUDA (pembrolizumab), combined with chemo, for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer &#40;NSCLC&#41;.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3367353-fda-grants-accelerated-review-mercks-keytruda-first-line-lung-cancer-action-date-october-30\" target=\"_blank\">FDA grants accelerated review for Merck's Keytruda for first-line lung cancer, action date October 30</a> (July 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3384253\" data-linked=\"FDA OKs Merck&#39;s Keytruda for first-line lung cancer; shares up 2%\" data-tweet=\"$MRK - FDA OKs Merck&#39;s Keytruda for first-line lung cancer; shares up 2% https://seekingalpha.com/news/3384253-fda-oks-mercks-keytruda-for-first-line-lung-cancer-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3384253-fda-oks-mercks-keytruda-for-first-line-lung-cancer-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384251\" data-ts=\"1534793583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXEL\" target=\"_blank\">EXEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384251-exelixis-continues-selloff-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exelixis continues selloff, down 7%</a></h4><ul><li>Exelixis (<a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a> <font color='red'>-7.2%</font>) is down again, this time on more than 70% higher volume. Shares have retreated almost&nbsp;<font color='red'>25%</font>&nbsp;since touching $23.19 on August 2, the first trading day after reporting Q2 results after the close on August 1.</li><li>Shares reversed the next day and have been going south since.</li><li>Management has hardly been behaving like the down move is a buying opportunity. CEO Michael Morrissey recently unloaded 400K shares. CMO Gisela Schwab and SVP P.J. Haley have sold shares as well.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3376888-exelixis-beats-0_12-beats-revenue\" target=\"_blank\">Exelixis beats by $0.12, beats on revenue</a> (Aug. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3384251\" data-linked=\"Exelixis continues selloff, down 7%\" data-tweet=\"$EXEL - Exelixis continues selloff, down 7% https://seekingalpha.com/news/3384251-exelixis-continues-selloff-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3384251-exelixis-continues-selloff-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384245\" data-ts=\"1534792035\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCM\" target=\"_blank\">CMCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384245-nomura-boosts-cheetah-mobile-to-buy-shares-nowplus-22\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nomura boosts Cheetah Mobile to Buy; shares now +22%</a></h4><ul>   <li>Cheetah Mobile (NYSE:<a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a>) has built on premarket gains, now <font color='green'>up 22.3%</font> on volume that's nearly seven times daily average, after revenue positivity in its <a href=\"https://seekingalpha.com/news/3384096-cheetah-mobile-12-percent-premarket-sees-sequential-revenue-growth-resuming\" target=\"_blank\">Q2 report</a>.</li>    <li>Pointing to a turn in revenue momentum, Nomura has upgraded its stance on the firm's ADRs to Buy, and boosted its target to $13 from $12.50.</li>    <li>Today's big gains bring the shares to $11.11, implying 17% further upside in Nomura's target.</li>    <li><a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a> today has hit its highest point in two month.</li>    <li><a href=\"https://seekingalpha.com/article/4200571-cheetah-mobile-inc-cmcm-ceo-sheng-fu-q2-2018-results-earnings-call-transcript\" target=\"_blank\">Earnings call transcript</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3384245\" data-linked=\"Nomura boosts Cheetah Mobile to Buy; shares now +22%\" data-tweet=\"$CMCM - Nomura boosts Cheetah Mobile to Buy; shares now +22% https://seekingalpha.com/news/3384245-nomura-boosts-cheetah-mobile-to-buy-shares-nowplus-22?source=tweet\" data-url=\"https://seekingalpha.com/news/3384245-nomura-boosts-cheetah-mobile-to-buy-shares-nowplus-22\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384239\" data-ts=\"1534791490\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLIR\" target=\"_blank\">FLIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384239-flir-systems-upgraded-blair-on-drone-av-growth-opportunities\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Flir Systems upgraded at Blair on drone, AV growth opportunities</a></h4><ul>     <li>Flir Systems (<a href='https://seekingalpha.com/symbol/FLIR' title='FLIR Systems, Inc.'>FLIR</a> <font color='green'>+2.2%</font>) is higher after William Blair <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12232310/flir-systems-has-growth-opportunities-in-data-drones-au\" target=\"_blank\">upgrades</a> shares to Outperform from Market Perform, expecting sales will be positively affected by a strong economy and enhanced product capability.</li>     <li>Flir's enhanced automation and software capabilities are rendering its sensors more powerful and driving adoption, and the company's thermal sensors will be common in autonomous vehicles over the longer term, which could be a major source of long-term upside, says Blair's Louis di Palma.</li>     <li>Flir's Nano drones have a significant opportunity to come into widespread use in the next five years, as the Department Of Defense is increasing its spending on drones by ~30%/year, di Palma says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384239\" data-linked=\"Flir Systems upgraded at Blair on drone, AV growth opportunities\" data-tweet=\"$FLIR - Flir Systems upgraded at Blair on drone, AV growth opportunities https://seekingalpha.com/news/3384239-flir-systems-upgraded-blair-on-drone-av-growth-opportunities?source=tweet\" data-url=\"https://seekingalpha.com/news/3384239-flir-systems-upgraded-blair-on-drone-av-growth-opportunities\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384238\" data-ts=\"1534791342\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCM\" target=\"_blank\">CMCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384238-technology-top-5-gainers-losers-of-2_55-pm-08-20-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 2.55 PM (08/20/2018)</a></h4><ul>     <li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/LTRX' title='Lantronix, Inc.'>LTRX</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corp.'>DDD</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/PTNR' title='Partner Communications Company Ltd.'>PTNR</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/FTR' title='Frontier Communications Corporation'>FTR</a> <font color='green'>+7%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/PDVW' title='pdvWireless, Inc.'>PDVW</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/UAVS' title='AgEagle'>UAVS</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CDLX' title='Cardlytics, Inc.'>CDLX</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight'>BOXL</a> <font color='red'>-8%</font>.</li>      &nbsp; </ul><div class=\"tiny-share-widget\" data-id=\"3384238\" data-linked=\"Technology - Top 5 Gainers / Losers as of 2.55 PM (08/20/2018)\" data-tweet=\"$CMCM $CMCM $LTRX - Technology - Top 5 Gainers / Losers as of 2.55 PM (08/20/2018) https://seekingalpha.com/news/3384238-technology-top-5-gainers-losers-of-2_55-pm-08-20-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3384238-technology-top-5-gainers-losers-of-2_55-pm-08-20-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384237\" data-ts=\"1534790915\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPTN\" target=\"_blank\">SPTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384237-wolfe-research-sees-challenging-climate-for-spartannash\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wolfe Research sees &#39;challenging&#39; climate for SpartanNash</a></h4><ul> <li>Wolfe Research checks in on SpartanNash (<a href='https://seekingalpha.com/symbol/SPTN' title='SpartanNash Company'>SPTN</a> <font color='green'>+1.4%</font>) following the company's in-line earnings report and below-consensus guidance update tied to timing factors and a product recall.</li> <li>Wolfe on SpartanNash: \"The operating climate remains challenging with rising costs and continued competition. While the timing factors should work themselves out and momentum in the Caito business should return over the coming quarters, in the short-run, these headwinds are overwhelming the success the company is seeing in the business, particularly in the legacy distribution platform which grew strongly in the quarter.\"</li> <li>The firm keeps a Peer Perform rating on the stock due to the headwinds.</li><li>Shares of SPTN are down 16% from a week ago.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3384237\" data-linked=\"Wolfe Research sees &#39;challenging&#39; climate for SpartanNash\" data-tweet=\"$SPTN - Wolfe Research sees &#39;challenging&#39; climate for SpartanNash https://seekingalpha.com/news/3384237-wolfe-research-sees-challenging-climate-for-spartannash?source=tweet\" data-url=\"https://seekingalpha.com/news/3384237-wolfe-research-sees-challenging-climate-for-spartannash\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384232\" data-ts=\"1534789862\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EA\" target=\"_blank\">EA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384232-ea-sets-open-beta-dates-for-battlefield-v\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EA sets open beta dates for &#39;Battlefield V&#39;</a></h4><ul>   <li>Electronic Arts (<a href=\"http://seekingalpha.com/symbol/EA\" target=\"_blank\">EA</a> <font color='red'>-0.2%</font>) has set the open beta for the latest entry in its key game franchise <i>Battlefield.</i></li>    <li>The open beta for Battlefield V <a href=\"https://seekingalpha.com/pr/17249182-ea-announces-battlefield-v-open-beta-will-begin-september-4-early-access-september-6\" target=\"_blank\">begins Sept. 4</a> for early-access players and Sept. 6 for all players on Origin for PC, Xbox One and PlayStation 4.</li>    <li>The game is boasting new real-time ray tracing graphic technology in partnership with Nvidia (<a href=\"http://seekingalpha.com/symbol/NVDA\" target=\"_blank\">NVDA</a> <font color='green'>+2.9%</font>).</li>    <li>Its worldwide availability is set for Oct. 19; pre-orders of the deluxe edition will offer access three days earlier, on Oct. 16, and Origin Access Premier members on PC will get access to the full game Oct. 11.</li>    <li>Since the first game in the series was released in 2002, tens of millions of players have played the franchise's entries.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384232\" data-linked=\"EA sets open beta dates for &#39;Battlefield V&#39;\" data-tweet=\"$EA $EA $NVDA - EA sets open beta dates for &#39;Battlefield V&#39; https://seekingalpha.com/news/3384232-ea-sets-open-beta-dates-for-battlefield-v?source=tweet\" data-url=\"https://seekingalpha.com/news/3384232-ea-sets-open-beta-dates-for-battlefield-v\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384227\" data-ts=\"1534788032\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PKD-OLD\" target=\"_blank\">PKD-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384227-energy-materials-top-5-gainers-losers-of-2-00-pm-08-20-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (08/20/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PKD-OLD' title='Parker Drilling Company'>PKD-OLD</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/BTG' title='B2Gold Corp.'>BTG</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/AMID' title='American Midstream Partners, LP'>AMID</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/CVRR' title='CVR Refining, LP'>CVRR</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/EGY' title='VAALCO Energy, Inc.'>EGY</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SNMP' title='Sanchez Midstream Partners LP'>SNMP</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384227\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (08/20/2018)\" data-tweet=\"$PKD-OLD $PKD $PED - Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (08/20/2018) https://seekingalpha.com/news/3384227-energy-materials-top-5-gainers-losers-of-2-00-pm-08-20-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3384227-energy-materials-top-5-gainers-losers-of-2-00-pm-08-20-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384225\" data-ts=\"1534787219\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIT\" target=\"_blank\">FIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384225-fitbit-launches-charge-3-tracker-sharesplus-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fitbit launches Charge 3 tracker; shares +4%</a></h4><ul>   <li>Fitbit (NYSE:<a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a>) is <font color='green'>up 4%</font> on a day where it launched a <a href=\"https://seekingalpha.com/pr/17248832-adding-multimedia-fitbit-launches-charge-3-number-one-fitness-tracker-now-better-ever\" target=\"_blank\">new fitness tracker</a> with up to a week of battery life.</li>    <li>The Charge 3 boasts swimproof design and a touchscreen and uses aluminum casing and Corning Gorilla Glass, and features more than 15 goal-based exercise modes.</li>    <li>It also has a range of accessory bands in different styles.</li>    <li>The Charge 3 is on online presale for $149.95 in two colors, with accessories ranging from $29.95-$49.95. It hits stores in the Americas and EMEA beginning in October.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384225\" data-linked=\"Fitbit launches Charge 3 tracker; shares +4%\" data-tweet=\"$FIT - Fitbit launches Charge 3 tracker; shares +4% https://seekingalpha.com/news/3384225-fitbit-launches-charge-3-tracker-sharesplus-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3384225-fitbit-launches-charge-3-tracker-sharesplus-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384220\" data-ts=\"1534786211\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LCI\" target=\"_blank\">LCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384220-craig-hallum-cuts-view-on-lannett-after-jerome-stevens-exit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Craig Hallum cuts view on Lannett after Jerome Stevens exit</a></h4><ul><li>In scant solace to Lannett Company (<a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc'>LCI</a> <font color='red'>-58.7%</font>) investors, Craig Hallum downgrades the stock to Neutral from Buy with a $7 (26% upside) price target on the announcement that Jerome Stevens will not renew its distribution deal for three products. Shares cratered on the news.</li><li>Lannett does not break out specific sales by product in its financials, but the three relevant categories, migraine, cardiovascular and thyroid deficiency, represented over 52% of the company's sales of $513.7M over the past three quarters.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3384050-jerome-stevens-nixes-distribution-deal-lannett-shares-26-percent-premarket\" target=\"_blank\">Jerome Stevens nixes distribution deal with Lannett; shares down 26% premarket</a> (Aug. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3384220\" data-linked=\"Craig Hallum cuts view on Lannett after Jerome Stevens exit\" data-tweet=\"$LCI - Craig Hallum cuts view on Lannett after Jerome Stevens exit https://seekingalpha.com/news/3384220-craig-hallum-cuts-view-on-lannett-after-jerome-stevens-exit?source=tweet\" data-url=\"https://seekingalpha.com/news/3384220-craig-hallum-cuts-view-on-lannett-after-jerome-stevens-exit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384219\" data-ts=\"1534785180\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALRN\" target=\"_blank\">ALRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384219-aileron-tries-to-right-ship-up-21\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aileron tries to right the ship; up 21%</a></h4><ul><li>Thinly traded nano cap Aileron Therapeutics (<a href='https://seekingalpha.com/symbol/ALRN' title='Aileron Therapeutics'>ALRN</a> <font color='green'>+20.5%</font>) is up on a 4x surge in volume, albeit on turnover of only 203K shares. The stock has been mired in a two-month downtrend during which it had surrendered 2/3 of its value before today's action.</li><li>A few weeks ago, it filed a prospectus for a $150M mixed shelf offering. At the end of June, it had $35.8M in <a href=\"https://www.sec.gov/Archives/edgar/data/1420565/000156459018019901/alrn-10q_20180630.htm#CONDENSED_BALANCE_SHEETS_UNAUDITED\" target=\"_blank\">quick assets</a> while operations consumed $14.4M in H1.</li><li>Lead candidate is <a href=\"https://www.aileronrx.com/pipeline/\" target=\"_blank\">ALRN-6924</a>, in Phase 1 development for certain blood cancers and Phase 1/2 for solid tumors or lymphomas.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384219\" data-linked=\"Aileron tries to right the ship; up 21%\" data-tweet=\"$ALRN - Aileron tries to right the ship; up 21% https://seekingalpha.com/news/3384219-aileron-tries-to-right-ship-up-21?source=tweet\" data-url=\"https://seekingalpha.com/news/3384219-aileron-tries-to-right-ship-up-21\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384217\" data-ts=\"1534784496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GWGH\" target=\"_blank\">GWGH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384217-financials-top-gainers-losers-of-1-00-pm-08-20-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top Gainers / Losers as of 1:00 PM (08/20/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GWGH' title='GWG Holdings'>GWGH</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/PPDF' title='PPDAI Group Inc.'>PPDF</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/NOAH' title='Noah Holdings Limited'>NOAH</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CLDC' title='China Lending Corporation'>CLDC</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/IHT' title='Innsuites Hospitality Trust'>IHT</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384217\" data-linked=\"Financials - Top Gainers / Losers as of 1:00 PM (08/20/2018)\" data-tweet=\"$GWGH $GWGH $FINV - Financials - Top Gainers / Losers as of 1:00 PM (08/20/2018) https://seekingalpha.com/news/3384217-financials-top-gainers-losers-of-1-00-pm-08-20-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3384217-financials-top-gainers-losers-of-1-00-pm-08-20-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384215\" data-ts=\"1534784291\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBOX\" target=\"_blank\">BBOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384215-black-boxplus-7_9-net-losses-narrow\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Black Box +7.9% as net losses narrow</a></h4><ul>   <li>Black Box (NASDAQ:<a href='https://seekingalpha.com/symbol/BBOX' title='Black Box Corporation'>BBOX</a>) is <font color='green'>up 7.9%</font> after its <a href=\"https://seekingalpha.com/news/3384185-black-box-reports-q1-results\" target=\"_blank\">Q1 results</a> where it narrowed net losses on a Y/Y and sequential basis and saw improving margins in North America.</li>    <li>Revenues declined 0.4% Y/Y (down 1.6% sequentially), but loss before taxes declined to $7.5M (from a year-ago loss of $14.2M), and net loss narrowed to $7.3M from $9.7M a year ago (and a loss of $51M last quarter).</li>    <li>Gross profit margin grew 80 basis points Y/Y to 28.2%. Margins improved in North America both in the commercial and federal businesses, while International Services margins declined.</li>    <li>It's getting ready to close on the $75M sale of its federal IT services business by Aug. 31.</li>    <li>Cash flow used in operations was $2.3M, down from cash flow use of $16.3M in the prior year.</li>    <li><a href=\"https://seekingalpha.com/filing/4143408\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3384215\" data-linked=\"Black Box +7.9% as net losses narrow\" data-tweet=\"$BBOX - Black Box +7.9% as net losses narrow https://seekingalpha.com/news/3384215-black-boxplus-7_9-net-losses-narrow?source=tweet\" data-url=\"https://seekingalpha.com/news/3384215-black-boxplus-7_9-net-losses-narrow\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384213\" data-ts=\"1534784218\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMNP\" target=\"_blank\">IMNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384213-immune-pharmas-bertilimumab-orphan-drug-in-u-s-for-rare-skin-blister-disorder-shares-down-43\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immune Pharma&#39;s bertilimumab an Orphan Drug in U.S. for rare skin blister disorder; shares down 43% ahead of reverse split and possible capital raise</a></h4><ul><li>Nano cap Immune Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IMNP' title='Immune Pharmaceuticals Inc.'>OTCQB:IMNP</a> <font color='red'>-43.3%</font>) is down on almost a 7x surge in volume despite <a href=\"https://seekingalpha.com/pr/17249056-bertilimumab-granted-orphan-drug-designation-treatment-bullous-pemphigoid\" target=\"_blank\">announcing </a>Orphan Drug status in the U.S. for bertilimumab for <a href=\"https://www.mayoclinic.org/diseases-conditions/bullous-pemphigoid/symptoms-causes/syc-20350414\" target=\"_blank\">bullous pemphigoid</a>&nbsp;&#40;BP&#41;, a rare skin disorder characterized by large fluid-filled blisters in areas that frequently flex such as the lower abdomen or armpits.</li><li>Several weeks ago, the company postponed its Special Meeting of Stockholders scheduled for Wednesday, August 22, to allow it time to appeal Nasdaq's decision to delist its shares due to its low bid price. The purpose of the meeting was to vote on a reverse stock split.</li><li>At the end of June, it had $1.5M in cash and equivalents while operations consumed $6.8M in H1.</li><li>Management says it plans to launch a Phase 2/3 clinical assessing bertilimumab in BP next year so a capital raise will be necessary.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384213\" data-linked=\"Immune Pharma&#39;s bertilimumab an Orphan Drug in U.S. for rare skin blister disorder; shares down 43% ahead of reverse split and possible capital raise\" data-tweet=\"$IMNP $IMNPQ - Immune Pharma&#39;s bertilimumab an Orphan Drug in U.S. for rare skin blister disorder; shares down 43% ahead of reverse split and possible capital raise https://seekingalpha.com/news/3384213-immune-pharmas-bertilimumab-orphan-drug-in-u-s-for-rare-skin-blister-disorder-shares-down-43?source=tweet\" data-url=\"https://seekingalpha.com/news/3384213-immune-pharmas-bertilimumab-orphan-drug-in-u-s-for-rare-skin-blister-disorder-shares-down-43\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384214\" data-ts=\"1534784216\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TJX\" target=\"_blank\">TJX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384214-tjx-companies-earnings-preview\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TJX Companies earnings preview</a></h4><ul><li>TJX Companies (<a href='https://seekingalpha.com/symbol/TJX' title='TJX Companies Inc.'>TJX</a> <font color='green'>+0.9%</font>) is due out with earnings tomorrow.</li><li>Analysts expect the the retailer to post revenue of $8.99B and EPS of $1.05 vs. the company's guidance range of $1.02 to $1.04.</li><li>Comparable sales are expected to be 2.1% for the quarter, on consistent gains across segments.</li><li>Full-year guidance from TJX is currently set at $37.7-39.9B for sales and $4.75-4.83, for EPS with both marks ahead of consensus.</li><li>Shares of TJX are up 16% since the company reported Q1 numbers.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384214\" data-linked=\"TJX Companies earnings preview\" data-tweet=\"$TJX - TJX Companies earnings preview https://seekingalpha.com/news/3384214-tjx-companies-earnings-preview?source=tweet\" data-url=\"https://seekingalpha.com/news/3384214-tjx-companies-earnings-preview\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384212\" data-ts=\"1534784073\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSC-OLD\" target=\"_blank\">SSC-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384212-midday-gainers-losers-08-20-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (08/20/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a> <font color='green'>+66%</font>. <a href='https://seekingalpha.com/symbol/GRIN' title='Grindrod Shipping Holdings Ltd.'>GRIN</a> <font color='green'>+48%</font>. <a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/ALRN' title='Aileron Therapeutics'>ALRN</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/AGMH' title='AGM Group Holdings Inc.'>AGMH</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SALM' title='Salem Media Group, Inc'>SALM</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/CHMA' title='Chiasma'>CHMA</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/GWGH' title='GWG Holdings'>GWGH</a> <font color='green'>+12%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc'>LCI</a> <font color='red'>-59%</font>. <a href='https://seekingalpha.com/symbol/NFEC' title='NF Energy Saving Corp.'>NFEC</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/DRIO' title='DarioHealth Corp.'>DRIO</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CLDC' title='China Lending Corporation'>CLDC</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/UAVS' title='AgEagle'>UAVS</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/YOGA' title='YogaWorks'>YOGA</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/STAF' title='Staffing 360 Solutions, Inc.'>STAF</a> <font color='red'>-9%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3384212\" data-linked=\"Midday Gainers / Losers (08/20/2018)\" data-tweet=\"$SSC-OLD $SSC-OLD $GRIN - Midday Gainers / Losers (08/20/2018) https://seekingalpha.com/news/3384212-midday-gainers-losers-08-20-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3384212-midday-gainers-losers-08-20-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384198\" data-ts=\"1534781293\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NMKEF\" target=\"_blank\">NMKEF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384198-nemaska-finalizes-5-year-supply-agreement-northvolt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nemaska finalizes a 5-year supply agreement With Northvolt</a></h4><ul>     <li>Nemaska Lithium Inc. (<a href='https://seekingalpha.com/symbol/NMKEF' title='Nemaska Lithium, Inc.'>OTCQX:NMKEF</a> <font color='green'>+2.4%</font>) signs an agreement to&nbsp; supply battery grade lithium hydroxide to Northvolt AB.</li>     <li>Nemaska Lithium <a href=\"https://seekingalpha.com/pr/17143768-nemaska-lithium-northvolt-announce-signature-agreement-principle-supply-lithium-hydroxide\" target=\"_blank\">announced an agreement in principle</a> with Northvolt. This agreement is now superseded by a definitive 5-year supply agreement.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3367957-nemaska-signs-lithium-hydroxide-supply-deal-lg-chem\" target=\"_blank\">Nemaska signs lithium hydroxide supply deal with LG Chem</a> (July 4)</li><li><a href=\"https://seekingalpha.com/pr/17248886-nemaska-lithium-finalizes-5-year-supply-agreement-northvolt\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3384198\" data-linked=\"Nemaska finalizes a 5-year supply agreement With Northvolt\" data-tweet=\"$NMKEF - Nemaska finalizes a 5-year supply agreement With Northvolt https://seekingalpha.com/news/3384198-nemaska-finalizes-5-year-supply-agreement-northvolt?source=tweet\" data-url=\"https://seekingalpha.com/news/3384198-nemaska-finalizes-5-year-supply-agreement-northvolt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384195\" data-ts=\"1534781193\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRY\" target=\"_blank\">TLRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384195-tilray-continues-rally-up-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tilray continues rally, up 10%</a></h4><ul><li>Cannabis outfit Tilray (<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color='green'>+15.7%</font>) continues its up move on modestly higher volume. Shares have rallied over&nbsp;<font color='green'>40%</font>&nbsp;since Citron Research announced a bullish view with a $45 fair value target.</li><li>Other cannabinoid-related firms are in the green as well.</li><li>Selected tickers: (ACBFF <font color='green'>+9.4%</font>)(<a href='https://seekingalpha.com/symbol/AERO' title='Aero Grow International, Inc.'>OTCQB:AERO</a> <font color='green'>+2.1%</font>)(<a href='https://seekingalpha.com/symbol/AMMJ' title='American Cannabis Company, Inc.'>OTCPK:AMMJ</a> <font color='green'>+7%</font>)(APHQF <font color='green'>+6.3%</font>)(<a href='https://seekingalpha.com/symbol/BLOZF' title='Cannabix Technologies Inc.'>OTCPK:BLOZF</a> <font color='green'>+14.2%</font>)(<a href='https://seekingalpha.com/symbol/CANN' title='General Cannabis Corp.'>OTCQX:CANN</a> <font color='green'>+17.1%</font>)(<a href='https://seekingalpha.com/symbol/CBDS' title='Cannabis Sativa, Inc.'>OTCQB:CBDS</a> <font color='green'>+34%</font>)(<a href='https://seekingalpha.com/symbol/CBIS' title='Cannabis Science, Inc.'>OTCPK:CBIS</a> <font color='green'>+4.6%</font>)(<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a> <font color='green'>+8.5%</font>)(<a href='https://seekingalpha.com/symbol/CNAB' title='United Cannabis Corp.'>OTCQB:CNAB</a> <font color='green'>+9.3%</font>)(<a href='https://seekingalpha.com/symbol/CVSI' title='CV Sciences, Inc.'>OTCQB:CVSI</a> <font color='green'>+27.7%</font>)(<a href='https://seekingalpha.com/symbol/EAPH' title='Easton Pharmaceuticals, Inc.'>OTCPK:EAPH</a> <font color='green'>+0.9%</font>)(<a href='https://seekingalpha.com/symbol/HEMP' title='Hemp, Inc.'>OTCPK:HEMP</a> <font color='green'>+3.9%</font>)(<a href='https://seekingalpha.com/symbol/HMLSF' title='Horizons Marijuana Life Sciences Index ETF'>OTC:HMLSF</a> <font color='green'>+4.8%</font>)(<a href='https://seekingalpha.com/symbol/MYHI' title='Mountain High Acquisitions Corp.'>OTCQB:MYHI</a> <font color='green'>+2.4%</font>)(<a href='https://seekingalpha.com/symbol/MNTR' title='Mentor Capital, Inc.'>OTCQX:MNTR</a> <font color='green'>+12%</font>)(<a href='https://seekingalpha.com/symbol/MSRT' title='MassRoots, Inc.'>OTCQB:MSRT</a> <font color='green'>+4.5%</font>)(<a href='https://seekingalpha.com/symbol/NTRR' title='Neutra Corp.'>OTCQB:NTRR</a> <font color='green'>+6%</font>)(<a href='https://seekingalpha.com/symbol/NGMC' title='Next Generation Management Corp.'>OTCPK:NGMC</a>)(<a href='https://seekingalpha.com/symbol/SPRWF' title='Supreme Cannabis Co Inc.'>OTCQX:SPRWF</a> <font color='green'>+2.8%</font>)(<a href='https://seekingalpha.com/symbol/VAPR' title='VaporBrands International, Inc.'>OTCPK:VAPR</a> <font color='green'>+12.2%</font>)(<a href='https://seekingalpha.com/symbol/VTMB' title='Vitamin Blue Inc'>OTCPK:VTMB</a> <font color='green'>+28.6%</font>)(<a href='https://seekingalpha.com/symbol/ZDPY' title='Zoned Properties, Inc.'>OTCQX:ZDPY</a> <font color='green'>+0.8%</font>)(<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a> <font color='green'>+13.6%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3384195\" data-linked=\"Tilray continues rally, up 10%\" data-tweet=\"$TLRY $TLRY $ACB - Tilray continues rally, up 10% https://seekingalpha.com/news/3384195-tilray-continues-rally-up-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3384195-tilray-continues-rally-up-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384194\" data-ts=\"1534781124\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DGLY\" target=\"_blank\">DGLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384194-digital-allyminus-3_8-amid-wider-losses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digital Ally -3.8% amid wider losses</a></h4><ul>    <li>Digital Ally (NASDAQ:<a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a>) is <font color='red'>off 3.8%</font> after posting <a href=\"https://seekingalpha.com/news/3384129-digital-ally-reports-q2-results\" target=\"_blank\">Q2 earnings</a> where gross profit jumped but net loss widened on valuation of debentures.</li>    <li>Revenues ticked up 2%, and gross profit rose 38% on lower cost of revenues.</li>    <li>SG&amp;A costs also fell by 17%, trimming operating losses to $1.44M. But valuation of secured convertible debentures had a negative impact of $843,000.</li>    <li>The company continues to fight patent battles on multiple fronts. \"Our law enforcement revenues declined over the prior period due to price-cutting, willful infringement of our patents and other actions by our competitors and adverse marketplace effects related to the patent litigation,\" it says, pointing to a rival body camera that disrupted the market and pressured its revenues.</li>    <li>Litigation has resumed in its patent case against Axon, it says, and following a Markman Order in Digital Ally's favor, fact discovery will close Sept. 17 and final pretrial conference has been set for Jan. 16, 2019.</li>    <li><a href=\"https://seekingalpha.com/pr/17248919-digital-ally-inc-announces-2018-second-quarter-operating-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3384194\" data-linked=\"Digital Ally -3.8% amid wider losses\" data-tweet=\"$DGLY - Digital Ally -3.8% amid wider losses https://seekingalpha.com/news/3384194-digital-allyminus-3_8-amid-wider-losses?source=tweet\" data-url=\"https://seekingalpha.com/news/3384194-digital-allyminus-3_8-amid-wider-losses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384192\" data-ts=\"1534780835\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SODA\" target=\"_blank\">SODA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384192-consumer-top-gainers-losers-of-12-00-pm-08-20-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 PM (08/20/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SODA' title='SodaStream International'>SODA</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/KOSS' title='Koss Corporation'>KOSS</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/TOWR' title='Tower International, Inc.'>TOWR</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/DFBG-OLD' title='Differential Brands Group Inc.'>DFBG-OLD</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/ELF' title='e.l.f. Beauty'>ELF</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SEED' title='Origin Agritech Limited'>SEED</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/NAKD' title='Naked Brand Group Limited'>NAKD</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384192\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 PM (08/20/2018)\" data-tweet=\"$SODA $SODA $KOSS - Consumer - Top Gainers / Losers as of 12:00 PM (08/20/2018) https://seekingalpha.com/news/3384192-consumer-top-gainers-losers-of-12-00-pm-08-20-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3384192-consumer-top-gainers-losers-of-12-00-pm-08-20-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384190\" data-ts=\"1534780278\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCB\" target=\"_blank\">MCB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384190-metropolitan-bank-price-target-estimates-cut-kbw-on-volatile-crypto-market\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Metropolitan Bank price-target, estimates cut by KBW on volatile crypto market</a></h4><ul><li>Metropolitan Bank (<a href='https://seekingalpha.com/symbol/MCB' title='Metropolitan Bank Holding Corp.'>MCB</a> <font color='red'>-2.4%</font>) price target cut to $55 from $66 and 2018 EPS estimate trimmed by 15% by KBW analyst Collyn Gilbert, Bloomberg reports.</li><li>Notes Q2 EPS slid 6.5% from Q1 as fee income fell by half, almost completely from lower crypto transaction income.</li><li>Gilbert sees lower activity likely to persist after two very strong quarters were driven by excess digital currency transactions.</li><li>Cuts 2019 EPS estimate by 20%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3383368-can-cryptocurrencies-recover\" target=\"_blank\">Can cryptocurrencies recover?</a> (Aug. 16)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3373406-metropolitan-bank-misses-0_11-misses-revenue\" target=\"_blank\">Metropolitan Bank misses by $0.11, misses on revenue</a> (July 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3384190\" data-linked=\"Metropolitan Bank price-target, estimates cut by KBW on volatile crypto market\" data-tweet=\"$MCB - Metropolitan Bank price-target, estimates cut by KBW on volatile crypto market https://seekingalpha.com/news/3384190-metropolitan-bank-price-target-estimates-cut-kbw-on-volatile-crypto-market?source=tweet\" data-url=\"https://seekingalpha.com/news/3384190-metropolitan-bank-price-target-estimates-cut-kbw-on-volatile-crypto-market\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384189\" data-ts=\"1534780156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OLLI\" target=\"_blank\">OLLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384189-ollies-rallies-after-two-notch-baml-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ollie&#39;s rallies after two-notch BAML upgrade</a></h4><ul><li>Shares of Ollie's Bargain Outlet Holdings (<a href='https://seekingalpha.com/symbol/OLLI' title='Ollie&#39;s Bargain Outlet Holdings'>OLLI</a> <font color='green'>+2.9%</font>) rally after a two-notch upgrade from Bank of America Merrill Lynch.</li><li>BAML moves Ollie's straight to a Buy rating from Underperform on its view that the market isn't factoring in the positive benefit for the retailer from the Toys 'R' Us store liquidations.</li><li>The price target on Ollie's is hiked straight to <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+BofAMerrill+Lynch+Upgrades+Ollies+Bargain+Outlet+%28OLLI%29+to+Buy/14530412.html\" target=\"_blank\">$88</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384189\" data-linked=\"Ollie&#39;s rallies after two-notch BAML upgrade\" data-tweet=\"$OLLI - Ollie&#39;s rallies after two-notch BAML upgrade https://seekingalpha.com/news/3384189-ollies-rallies-after-two-notch-baml-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3384189-ollies-rallies-after-two-notch-baml-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384185\" data-ts=\"1534779562\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBOX\" target=\"_blank\">BBOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384185-black-box-reports-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Black Box reports Q1 results</a></h4><ul><li>Black Box (NASDAQ:<a href='https://seekingalpha.com/symbol/BBOX' title='Black Box Corporation'>BBOX</a>): Q1 Non-GAAP EPS of -$0.28; GAAP EPS of -$0.48.</li><li>Revenue of $190.8M (-0.4% Y/Y)</li><li>Shares <font color='green'>+8%</font>.</li><li><a href='https://seekingalpha.com/filing/4143408'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3384185\" data-linked=\"Black Box reports Q1 results\" data-tweet=\"$BBOX - Black Box reports Q1 results https://seekingalpha.com/news/3384185-black-box-reports-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3384185-black-box-reports-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384182\" data-ts=\"1534779408\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384182-tonix-pharma-still-clawing-back-up-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tonix Pharma still clawing back, up 8%</a></h4><ul><li>Nano cap Tonix Pharmaceutical Holding (<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a> <font color='green'>+7.9%</font>) jumps on more than triple normal volume. Shares have regained almost&nbsp;<font color='green'>50%</font>&nbsp;since touching $0.89 on July 27 after announcing the Tonmya flop in PTSD.</li><li>At the end of June, it had $16.7M in cash and equivalents. Operations consumed $12.3M in H1.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3374900-tonix-pharma-ptsd-study-fails-shares-halted\" target=\"_blank\">Tonix Pharma PTSD study fails; shares halted</a> (July 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3384182\" data-linked=\"Tonix Pharma still clawing back, up 8%\" data-tweet=\"$TNXP - Tonix Pharma still clawing back, up 8% https://seekingalpha.com/news/3384182-tonix-pharma-still-clawing-back-up-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3384182-tonix-pharma-still-clawing-back-up-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384180\" data-ts=\"1534778974\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOC\" target=\"_blank\">BIOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384180-biocept-continues-slide-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biocept continues slide, down 7%</a></h4><ul><li>Nano cap Biocept (<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color='red'>-7.1%</font>) resumes its downward march on light volume. Shares have sold off&nbsp;<font color='red'>74%</font>&nbsp;since touching $12.15 on July 13 shortly after announcing a rights offering and distribution deal for its liquid biopsy tests.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384180\" data-linked=\"Biocept continues slide, down 7%\" data-tweet=\"$BIOC - Biocept continues slide, down 7% https://seekingalpha.com/news/3384180-biocept-continues-slide-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3384180-biocept-continues-slide-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384177\" data-ts=\"1534778673\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TENB\" target=\"_blank\">TENB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384177-tenableplus-2_5-analysts-launch-post-ipo-coverage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tenable +2.5% as analysts launch post-IPO coverage</a></h4><ul>   <li>Digital security firm Tenable Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/TENB' title='Tenable Holdings'>TENB</a>) is <font color='green'>up 2.5%</font> amid a round of analyst initiations, a little after three weeks since the stock had its <a href=\"https://seekingalpha.com/news/3373923-tenable-announces-pricing-ipo\" target=\"_blank\">coming-out on Nasdaq</a>.</li>    <li>A bullish price target of $41, implying 28% upside, comes from IPO co-manager BTIG, which acknowledges the shares aren't cheap but that the company will see more than 30% compound annual growth in revenue over the coming three years, driving cash flow. (h/t Bloomberg)</li>    <li>Deutsche Bank (also a joint lead on the offering) has its target at $40 based on a \"compelling\" growth profile and solid valuation compared to Tenable's high-growth peers. Another co-lead, Morgan Stanley, is more cautious with a $31 price target but also sees healthy revenue growth (more than 25% for years) and says Tenable's in the center of an attractive cybersecurity market.</li>    <li>Shares are already up 40% from the July IPO pricing.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384177\" data-linked=\"Tenable +2.5% as analysts launch post-IPO coverage\" data-tweet=\"$TENB - Tenable +2.5% as analysts launch post-IPO coverage https://seekingalpha.com/news/3384177-tenableplus-2_5-analysts-launch-post-ipo-coverage?source=tweet\" data-url=\"https://seekingalpha.com/news/3384177-tenableplus-2_5-analysts-launch-post-ipo-coverage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384175\" data-ts=\"1534778349\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELOX\" target=\"_blank\">ELOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384175-elox-pharma-continues-selloff-down-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Elox Pharma continues selloff, down 3%</a></h4><ul><li>Thinly traded micro cap Elox Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ELOX' title='Eloxx Pharmaceuticals, Inc.'>ELOX</a> <font color='red'>-2.7%</font>) is down on below-average volume. Shares have dropped over&nbsp;<font color='red'>27%</font>&nbsp;since last week.</li><li>Several weeks ago, the company announced that a Phase 2 clinical trial evaluating lead candidate ELX-02 in cystic fibrosis and cystinosis should launch next quarter.</li><li>Last week, SunTrust <a href=\"https://www.tickerreport.com/banking-finance/3732056/q3-2018-eps-estimates-for-eloxx-pharmaceuticals-cut-by-suntrust-banks-elox.html\" target=\"_blank\">cut its Q3 EPS target</a> to a loss of ($0.42)/share from ($0.22) although it maintained its Buy rating.</li><li>At the end of June, it had $63.4M in cash and equivalents which it says should be sufficient to fund operations into 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384175\" data-linked=\"Elox Pharma continues selloff, down 3%\" data-tweet=\"$ELOX - Elox Pharma continues selloff, down 3% https://seekingalpha.com/news/3384175-elox-pharma-continues-selloff-down-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3384175-elox-pharma-continues-selloff-down-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384173\" data-ts=\"1534777703\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384173-big-pharma-in-green-in-early-trade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big Pharma in the green in early trade</a></h4><ul><li>Buying has picked up in the large cap pharma space. Last week's bullish news included an FDA nod for Bristol-Myers Squibb's (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-0.4%</font>) Opdivo in small cell lung cancer and Teva Pharmaceutical industries' generic EpiPen.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/BHC' title='Bausch Health Companies Inc.'>BHC</a> <font color='green'>+2.2%</font>)(<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a> <font color='green'>+1.2%</font>)(<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color='green'>+0.1%</font>)(<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='green'>+3.2%</font>)(<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='green'>+1.7%</font>)(<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a> <font color='green'>+0.4%</font>)(<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color='green'>+1.6%</font>)(<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='green'>+0.7%</font>)(<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a> <font color='green'>+0.8%</font>)(<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color='green'>+0.3%</font>)(<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='green'>+1%</font>)(<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a> <font color='green'>+0.5%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3384173\" data-linked=\"Big Pharma in the green in early trade\" data-tweet=\"$BMY $BMY $BHC - Big Pharma in the green in early trade https://seekingalpha.com/news/3384173-big-pharma-in-green-in-early-trade?source=tweet\" data-url=\"https://seekingalpha.com/news/3384173-big-pharma-in-green-in-early-trade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384174\" data-ts=\"1534777688\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMRT\" target=\"_blank\">SMRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384174-stein-mart-rallies-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stein Mart rallies ahead of earnings</a></h4><ul> <li>Stein Mart (NASDAQ:<a href='https://seekingalpha.com/symbol/SMRT' title='Stein Mart, Inc.'>SMRT</a>) trades <font color='green'>up 8.78%</font> ahead of the retailer's Q2 earnings report due out on Wednesday.</li> <li>There aren't enough Wall Street analysts covering the stock to lead to a consensus estimate for the quarter.</li><li>Stein Mart posted a double-digit rally after the company's Q1 report and guided for flat to low single-digit increases in comparable sales for Q2.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3384174\" data-linked=\"Stein Mart rallies ahead of earnings\" data-tweet=\"$SMRT - Stein Mart rallies ahead of earnings https://seekingalpha.com/news/3384174-stein-mart-rallies-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3384174-stein-mart-rallies-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384168\" data-ts=\"1534777226\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384168-healthcare-top-5-gainers-losers-of-11-00-08-20-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 AM (08/20/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/CHMA' title='Chiasma'>CHMA</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/CBPO' title='China Biologic Products, Inc.'>CBPO</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/AMRX' title='Amneal Pharmaceuticals, Inc.'>AMRX</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc'>LCI</a> <font color='red'>-59%</font>. <a href='https://seekingalpha.com/symbol/ELOX' title='Eloxx Pharmaceuticals, Inc.'>ELOX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/IDRA' title='Idera Pharmaceuticals, Inc.'>IDRA</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/AKAO' title='Achaogen'>AKAO</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384168\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 AM (08/20/2018)\" data-tweet=\"$TNXP $TNXP $CHMA - Healthcare - Top 5 Gainers / Losers as of 11:00 AM (08/20/2018) https://seekingalpha.com/news/3384168-healthcare-top-5-gainers-losers-of-11-00-08-20-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3384168-healthcare-top-5-gainers-losers-of-11-00-08-20-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384160\" data-ts=\"1534776113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384160-treasury-yields-lower-gundlach-warns-of-short-squeeze\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Treasury yields lower; Gundlach warns of short squeeze</a></h4><ul><li>Jeff Gundlach over weekend <a href=\"https://twitter.com/TruthGundlach/status/1030558361295630336\" target=\"_blank\">took note of a massive</a> increase in short interest in 10- and 30-year Treasury bond futures. \"Highest for both in history, by far,\" he says. \"Could cause quite a squeeze.\"</li><li>The current action isn't exactly a squeeze, but the 10-year yield has been trending lower this month. It's down another 2.5 basis points today to 2.83% after starting August at just above 3%.</li><li><a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='green'>+0.6%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='red'>-1.2%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>, <a href='https://seekingalpha.com/symbol/TMV' title='Direxion Daily 20+ Year Treasury Bear 3x Shares ETF'>TMV</a>, <a href='https://seekingalpha.com/symbol/TBF' title='ProShares Short 20+ Year Treasury ETF'>TBF</a>, <a href='https://seekingalpha.com/symbol/EDV' title='Vanguard Extended Duration Treasury ETF'>EDV</a>, <a href='https://seekingalpha.com/symbol/TMF' title='Direxion Daily 30-Year Treasury Bull 3x Shares ETF'>TMF</a>, <a href='https://seekingalpha.com/symbol/TTT' title='ProShares UltraPro Short 20+ Year Treasury ETF'>TTT</a>, <a href='https://seekingalpha.com/symbol/ZROZ' title='PIMCO 25+ Year Zero Coupon U.S. Treasury Index ETF'>ZROZ</a>, <a href='https://seekingalpha.com/symbol/VGLT' title='Vanguard Long-Term Treasury ETF'>VGLT</a>, <a href='https://seekingalpha.com/symbol/TLH' title='iShares 10-20 Year Treasury Bond ETF'>TLH</a>, <a href='https://seekingalpha.com/symbol/UBT' title='ProShares Ultra 20+ Year Treasury ETF'>UBT</a>, <a href='https://seekingalpha.com/symbol/SPTL' title='SPDR Portfolio Long Term Treasury ETF'>SPTL</a>, <a href='https://seekingalpha.com/symbol/DLBS' title='iPath U.S. Treasury Long Bond Bear ETN'>DLBS</a>, <a href='https://seekingalpha.com/symbol/VUSTX' title='Vanguard Long Term Treasury Fund Inv'>VUSTX</a>, <a href='https://seekingalpha.com/symbol/TYBS' title='Direxion Daily 20+ Year Treasury Bear 1x Shares ETF'>TYBS</a>, <a href='https://seekingalpha.com/symbol/DLBL' title='iPath U.S. Treasury Long Bond Bull ETN'>DLBL</a>, <a href='https://seekingalpha.com/symbol/OPER' title='ClearShares Ultra-Short Maturity ETF'>OPER</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3384160\" data-linked=\"Treasury yields lower; Gundlach warns of short squeeze\" data-tweet=\"$TLT $TBT $TMV - Treasury yields lower; Gundlach warns of short squeeze https://seekingalpha.com/news/3384160-treasury-yields-lower-gundlach-warns-of-short-squeeze?source=tweet\" data-url=\"https://seekingalpha.com/news/3384160-treasury-yields-lower-gundlach-warns-of-short-squeeze\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384158\" data-ts=\"1534775730\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BABA\" target=\"_blank\">BABA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384158-ft-alibabas-ant-financial-delaying-ipo-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FT: Alibaba&#39;s Ant Financial delaying IPO again</a></h4><ul>   <li>An initial public offering for Ant Financial, payments arm of Alibaba (<a href=\"http://seekingalpha.com/symbol/BABA\" target=\"_blank\">BABA</a> <font color='green'>+1.6%</font>), is being <a href=\"https://www.ft.com/content/4703b2c0-9a18-11e8-ab77-f854c65a4465\" target=\"_blank\">pushed back yet again</a>, the <i>Financial Times</i> reports.</li>    <li>The listing seemed imminent after Ant <a href=\"https://seekingalpha.com/news/3362582-ant-financial-raises-14b-ahead-ipo\" target=\"_blank\">raised a staggering $14B</a> in a June fund-raising round.</li>    <li>Now two sources tell <i>FT</i> that a listing is unlikely before the end of 2019 and one says it's \"years\" away.</li>    <li>That comes as profitability has been wiped out amid heavy cash burn and competition for market share with its counterpart payments division at Tencent (<a href=\"http://seekingalpha.com/symbol/TCEHY\" target=\"_blank\">TCEHY</a> <font color='green'>+0.9%</font>). And Beijing has been cracking down on nonbank financial service firms.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384158\" data-linked=\"FT: Alibaba&#39;s Ant Financial delaying IPO again\" data-tweet=\"$BABA $BABA $TCEHY - FT: Alibaba&#39;s Ant Financial delaying IPO again https://seekingalpha.com/news/3384158-ft-alibabas-ant-financial-delaying-ipo-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3384158-ft-alibabas-ant-financial-delaying-ipo-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384157\" data-ts=\"1534775673\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384157-teva-continues-rebound-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva continues rebound, up 4%</a></h4><ul><li>Teva Pharmaceutical Industries (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='green'>+4.3%</font>) is up on modestly higher volume in early trade. Shares have rallied ~13% since last week when the FDA OK'd its generic EpiPen and it announced positive late-stage data on fasinumab.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384157\" data-linked=\"Teva continues rebound, up 4%\" data-tweet=\"$TEVA - Teva continues rebound, up 4% https://seekingalpha.com/news/3384157-teva-continues-rebound-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3384157-teva-continues-rebound-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384151\" data-ts=\"1534775257\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UUU\" target=\"_blank\">UUU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384151-universal-security-instruments-up-6-post-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Universal Security Instruments up 6% post Q1 results</a></h4><ul><li>Universal Security Instruments (<a href='https://seekingalpha.com/symbol/UUU' title='Universal Security Instruments, Inc'>UUU</a> <font color='green'>+6.6%</font>) reported Q1 sales growth of 22% Y/Y to $4.05M and net loss of $438k or $0.19 (-19.3% Y/Y).</li><li>Inventory was at $5.86M (+32.5% Y/Y).</li><li>Company had cash balance of $77k as of June 30, 2018, as compared to $246.51K.</li><li>Our pattern of higher sales has continued into the June quarter and we are anticipating this trend to continue. We do not know, at this time, what affect, if any, the new tariffs imposed by the Trump Administration on Chinese products will have on the Company. To date, only our ground fault circuit interrupters, which constitute only a small portion of our sales, have been included in products subject to the new tariffs, and the next group of tariffs are expected to be announced at the end of September. We are monitoring the tariff situation and once the final list is issued we will determine the strategies to follow,\" stated Harvey Grossblatt, President and CEO.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3384060-universal-security-instruments-reports-q1-results\" target=\"_blank\">Universal Security Instruments reports Q1 results</a> (Aug. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3384151\" data-linked=\"Universal Security Instruments up 6% post Q1 results\" data-tweet=\"$UUU - Universal Security Instruments up 6% post Q1 results https://seekingalpha.com/news/3384151-universal-security-instruments-up-6-post-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3384151-universal-security-instruments-up-6-post-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384148\" data-ts=\"1534774504\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REED\" target=\"_blank\">REED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384148-reeds-falls-after-pepsico-sodastream-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reed&#39;s falls after PepsiCo-SodaStream deal</a></h4><ul> <li>Reed's (NYSEMKT:<a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a>) is <font color='red'>down 5.01%</font> after PepsiCo acquires SodaStream.</li> <li>Investors may be factoring in a lower M&amp;A premium on Reed's following the PepsiCo move.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3384013-pepsico-buy-sodastream-3_2b\" target=\"_blank\">PepsiCo to buy SodaStream for $3.2B</a> (Aug. 20)</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3384045-details-pepsico-sodastream-deal\" target=\"_blank\">More details on the PepsiCo-SodaStream deal</a> (Aug. 20)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3384143-pepsico-bidder-sodastream\" target=\"_blank\">PepsiCo only bidder for SodaStream</a> (Aug. 20)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384148\" data-linked=\"Reed&#39;s falls after PepsiCo-SodaStream deal\" data-tweet=\"$REED - Reed&#39;s falls after PepsiCo-SodaStream deal https://seekingalpha.com/news/3384148-reeds-falls-after-pepsico-sodastream-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3384148-reeds-falls-after-pepsico-sodastream-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384145\" data-ts=\"1534774296\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZZHGF\" target=\"_blank\">ZZHGF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384145-china-s-online-insurer-zhongan-to-receive-strategic-investment-from-softbank-vision-fund\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China\u2019s online insurer ZhongAn to receive strategic investment from SoftBank vision fund</a></h4><ul>     <li>ZhongAn Online P&amp;C Insurance Co. (<a href='https://seekingalpha.com/symbol/ZZHGF' title='ZhongAn Online P & C Insurance Co., Ltd.'>OTCPK:ZZHGF</a>) says that its subsidiary and SoftBank Vision Fund have entered into a Shareholder agreement to boost ZhongAn&rsquo;s technology solutions businesses outside China.</li>     <li>ZhongAn International will establish a new operating entity to partner with SoftBank in exploring international opportunities; SoftBank Vision Fund will participate as a strategic investor.</li><li>The amount of the investment was not disclosed.</li><li><a href=\"https://www.insurancejournal.com/news/international/2018/08/20/498578.htm\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3384145\" data-linked=\"China\u2019s online insurer ZhongAn to receive strategic investment from SoftBank vision fund\" data-tweet=\"$ZZHGF - China\u2019s online insurer ZhongAn to receive strategic investment from SoftBank vision fund https://seekingalpha.com/news/3384145-china-s-online-insurer-zhongan-to-receive-strategic-investment-from-softbank-vision-fund?source=tweet\" data-url=\"https://seekingalpha.com/news/3384145-china-s-online-insurer-zhongan-to-receive-strategic-investment-from-softbank-vision-fund\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384139\" data-ts=\"1534773632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NWS\" target=\"_blank\">NWS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384139-news-corp-slips-ms-downgrades-on-foxtel-competition\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">News Corp. slips as MS downgrades on Foxtel competition</a></h4><ul>   <li>News Corp. is sharply lower today (<a href='https://seekingalpha.com/symbol/NWS' title='News Corporation'>NWS</a> <font color='red'>-4.7%</font>, <a href='https://seekingalpha.com/symbol/NWSA' title='News Corporation'>NWSA</a> <font color='red'>-4%</font>) with Morgan Stanley cutting shares to Underweight after a look at Australian unit Foxtel.</li>    <li>Foxtel will likely need to rebase earnings lower as its existing subscriber base on cable/satellite (and its high ARPU) come under pressure. Meanwhile, amid competition from Netflix and streaming services, Foxtel's own plans for a streaming sports service could be an \"exciting opportunity\" if it's bold about pricing, says analyst Andrew McLeod. (h/t Bloomberg)</li>    <li>His price target on <a href='https://seekingalpha.com/symbol/NWSA' title='News Corporation'>NWSA</a> is $12.50, down from $17 and now implying 6.4% downside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384139\" data-linked=\"News Corp. slips as MS downgrades on Foxtel competition\" data-tweet=\"$NWS $NWS $NWSA - News Corp. slips as MS downgrades on Foxtel competition https://seekingalpha.com/news/3384139-news-corp-slips-ms-downgrades-on-foxtel-competition?source=tweet\" data-url=\"https://seekingalpha.com/news/3384139-news-corp-slips-ms-downgrades-on-foxtel-competition\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384137\" data-ts=\"1534773530\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACIU\" target=\"_blank\">ACIU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384137-ac-immune-advancing-anti-abeta-vaccine-aciminus-24-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AC Immune advancing anti-Abeta vaccine ACI-24; shares up 1%</a></h4><ul><li>AC Immune SA (<a href='https://seekingalpha.com/symbol/ACIU' title='AC Immune SA'>ACIU</a> <font color='green'>+1.1%</font>) <a href=\"https://seekingalpha.com/pr/17248480-ac-immune-announces-important-clinical-milestones-aciminus-24-vaccine-alzheimers-disease\" target=\"_blank\">announces </a>two clinical milestone related to anti-Abeta vaccine candidate ACI-24.</li><li>A Phase 2 study in patients with mild Alzheimer's disease &#40;AD&#41; is underway aiming to confirm the positive trends observed in the previous Phase 1 trial.</li><li>The high dose cohort in its Phase 1b study in adults with Down syndrome with AD-like characteristics is now fully enrolled. Interim data from the low dose cohort, fully enrolled a year ago, should be available later this year.</li><li>The company says ACI-24 is designed to stimulate the immune system to produce antibodies that target Abeta proteins to prevent plaque accumulation and enhance plaque clearance.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384137\" data-linked=\"AC Immune advancing anti-Abeta vaccine ACI-24; shares up 1%\" data-tweet=\"$ACIU - AC Immune advancing anti-Abeta vaccine ACI-24; shares up 1% https://seekingalpha.com/news/3384137-ac-immune-advancing-anti-abeta-vaccine-aciminus-24-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3384137-ac-immune-advancing-anti-abeta-vaccine-aciminus-24-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384127\" data-ts=\"1534772224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFY\" target=\"_blank\">INFY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384127-infosysminus-2_6-after-morgan-stanley-downgrade-cfo-resignation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Infosys -2.6 after Morgan Stanley downgrade, CFO resignation</a></h4><ul>   <li>Infosys (NASDAQ:<a href='https://seekingalpha.com/symbol/INFY' title='Infosys Limited, Inc.'>INFY</a>) is <font color='red'>off 2.6%</font> to start the week on Nasdaq after a downgrade to Equal Weight by Morgan Stanley, from Overweight.</li>    <li>The company also accepted the resignation of M.D. Ranganath as its chief financial officer. Ranganath is moving on to professional opportunities in new areas, and will remain in the position until Nov. 16.</li>    <li>Morgan Stanley set its price target to 1,450 rupees; that now implies 4.7% upside after shares <font color='red'>fell 3.2%</font> in Mumbai today.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384127\" data-linked=\"Infosys -2.6 after Morgan Stanley downgrade, CFO resignation\" data-tweet=\"$INFY - Infosys -2.6 after Morgan Stanley downgrade, CFO resignation https://seekingalpha.com/news/3384127-infosysminus-2_6-after-morgan-stanley-downgrade-cfo-resignation?source=tweet\" data-url=\"https://seekingalpha.com/news/3384127-infosysminus-2_6-after-morgan-stanley-downgrade-cfo-resignation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384124\" data-ts=\"1534771711\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPACE\" target=\"_blank\">SPACE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384124-spacex-shareholders-weigh-in-on-tesla\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SpaceX shareholders weigh in on Tesla</a></h4><ul> <li>Axios says it has <a href=\"https://www.axios.com/newsletters/axios-pro-rata-f057ff59-f057-445a-bfbc-96a373202d15.html\" target=\"_blank\">talked</a> to several SpaceX (<a href='https://seekingalpha.com/symbol/SPACE' title='SpaceX'>SPACE</a>) shareholders about reports that the company could be involved in helping to finance a go-private Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) plan.</li> <li>\"They will go nuts if SpaceX itself tries to finance the Tesla buyout, at least in any meaningful way,\" reports back Dan Primack.</li> <li>\"They have the Musk company with profits and a deep management bench, and see no reason to marry it with the opposite. Particularly given all the conflicts of interest and possible regulatory headaches,\" he adds.</li><li>Of course, Musk as a very large SpaceX shareholder could pledge his own shares as part of a Tesla privatization bid.</li><li>TSLA&nbsp;<font color='red'>-4.35%</font>&nbsp;premarket to $292.16.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3384124\" data-linked=\"SpaceX shareholders weigh in on Tesla\" data-tweet=\"$SPACE $SPACE $TSLA - SpaceX shareholders weigh in on Tesla https://seekingalpha.com/news/3384124-spacex-shareholders-weigh-in-on-tesla?source=tweet\" data-url=\"https://seekingalpha.com/news/3384124-spacex-shareholders-weigh-in-on-tesla\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>297&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384121\" data-ts=\"1534771352\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VEON\" target=\"_blank\">VEON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384121-veonplus-2_5-hsbc-bumps-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veon +2.5% as HSBC bumps to Buy</a></h4><ul>    <li>Veon ADRs (NASDAQ:<a href='https://seekingalpha.com/symbol/VEON' title='VEON Ltd. ADS'>VEON</a>) are <font color='green'>up 2.5%</font> premarket after an upgrade to Buy at HSBC.</li>    <li>The firm raised its price target to $3.60, implying upside of 29%.</li>    <li><a href='https://seekingalpha.com/symbol/VEON' title='VEON Ltd. ADS'>VEON</a> is <font color='red'>down 27.6%</font> YTD though it's <font color='green'>rebounded 6.5%</font> over the past quarter.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384121\" data-linked=\"Veon +2.5% as HSBC bumps to Buy\" data-tweet=\"$VEON - Veon +2.5% as HSBC bumps to Buy https://seekingalpha.com/news/3384121-veonplus-2_5-hsbc-bumps-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3384121-veonplus-2_5-hsbc-bumps-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384119\" data-ts=\"1534771153\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGS\" target=\"_blank\">AGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384119-union-gaming-stays-positive-on-playags\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Union Gaming stays positive on PlayAGS</a></h4><ul> <li>Union Gaming keeps a Buy rating on PlayAGS (NYSE:<a href='https://seekingalpha.com/symbol/AGS' title='PlayAGS, Inc.'>AGS</a>) after Q2 results came in ahead of expectations.</li> <li>Analyst Jonh Decree notes that the recent 5.5M secondary offering on the behalf of Apollo did little to dent PlayAGS' share price momentum.</li> <li>\"We view the continued exit of Apollo ultimately as a valuation positive as it increases trading liquidity and float,\" writes DeCree.</li> <li>Union Gaming takes it price target on PlayAGS to $35 from $30.</li><li>Shares of PlayAGS are up 35% over the last 90 days.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384119\" data-linked=\"Union Gaming stays positive on PlayAGS\" data-tweet=\"$AGS - Union Gaming stays positive on PlayAGS https://seekingalpha.com/news/3384119-union-gaming-stays-positive-on-playags?source=tweet\" data-url=\"https://seekingalpha.com/news/3384119-union-gaming-stays-positive-on-playags\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384118\" data-ts=\"1534771071\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSC-OLD\" target=\"_blank\">SSC-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384118-premarket-gainers-of-9-05-08-20-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (08/20/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a> <font color='green'>+106%</font>&nbsp;on electric bus <a href=\"https://seekingalpha.com/news/3384093-seven-stars-group-skyrockets-electric-bus-deal\" target=\"_blank\">deal</a>.</li>     <li><a href='https://seekingalpha.com/symbol/BBOX' title='Black Box Corporation'>BBOX</a> <font color='green'>+17%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3384022-black-box-sell-federal-government-services-business\" target=\"_blank\">selling</a> its Federal Government IT Services Business.</li>     <li><a href='https://seekingalpha.com/symbol/CBPO' title='China Biologic Products, Inc.'>CBPO</a> <font color='green'>+15%</font>&nbsp;on $118/share <a href=\"https://seekingalpha.com/news/3384092-china-biologic-18-percent-premarket-118-share-bid\" target=\"_blank\">bid</a>.</li>     <li><a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a> <font color='green'>+13%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3384077-cheetah-mobile-misses-0_49-beats-revenue\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/LKM' title='Link Motion Inc.'>LKM</a> <font color='green'>+11%</font>&nbsp;on a <a href=\"https://seekingalpha.com/news/3384101-link-motion-plus-19_6-percent-announcing-business-cooperation-alibaba-groups-online-travel\" target=\"_blank\">business cooperation</a> with Alibaba Group's online travel agency Fliggy.</li>     <li><a href='https://seekingalpha.com/symbol/SODA' title='SodaStream International'>SODA</a> <font color='green'>+10%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3384013-pepsico-buy-sodastream-3_2b\" target=\"_blank\">acquired</a> by Pepsico.</li>     <li><a href='https://seekingalpha.com/symbol/SSKN' title='STRATA Skin Sciences, Inc'>SSKN</a> <font color='green'>+8%</font>&nbsp;on XTRAC laser <a href=\"https://seekingalpha.com/news/3384097-strata-skin-sciences-inks-xtrac-laser-deal-large-dermatology-group-shares-5-percent-premarket\" target=\"_blank\">deal</a> with large dermatology group.</li>     <li><a href='https://seekingalpha.com/symbol/EL' title='Estee Lauder Companies, Inc. &#40;The&#41;'>EL</a> <font color='green'>+5%</font>&nbsp;on Q4 <a href=\"https://seekingalpha.com/news/3384040-estee-lauder-beats-0_05-beats-revenue\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a> <font color='green'>+5%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17248744-fractionated-dosing-improves-tolerability-safety-cellectar-s-clr-131-r-r-multiple-myeloma\" target=\"_blank\">data</a> from Cohort 5 of the company&rsquo;s ongoing Phase 1b clinical trial evaluating CLR 131 for the treatment of relapsed/refractory multiple myeloma.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384118\" data-linked=\"Premarket Gainers as of 9:05 am (08/20/2018)\" data-tweet=\"$SSC-OLD $SSC-OLD $BBOX - Premarket Gainers as of 9:05 am (08/20/2018) https://seekingalpha.com/news/3384118-premarket-gainers-of-9-05-08-20-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3384118-premarket-gainers-of-9-05-08-20-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384112\" data-ts=\"1534770555\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LCI\" target=\"_blank\">LCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384112-premarket-losers-of-9-05-8-20-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (8/20/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc'>LCI</a>&nbsp;<font color='red'>-54%</font>&nbsp;on providing <a href=\"https://seekingalpha.com/news/3384050-jerone-stevens-nixes-distribution-deal-lannett-shares-26-percent-premarket\" target=\"_blank\">update</a> on contract renewal with Jerome Stevens Pharmaceuticals.</li><li><a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3384048-izea-announces-name-change-cusip-change\" target=\"_blank\">announcing</a> name and CUSIP change.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384112\" data-linked=\"Premarket Losers as of 9:05 am (8/20/2018)\" data-tweet=\"$LCI $LCI $IZEA - Premarket Losers as of 9:05 am (8/20/2018) https://seekingalpha.com/news/3384112-premarket-losers-of-9-05-8-20-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3384112-premarket-losers-of-9-05-8-20-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384109\" data-ts=\"1534770361\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVO\" target=\"_blank\">NVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384109-novos-oral-semaglutide-successful-in-late-stage-t2d-study-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novo&#39;s oral semaglutide successful in late-stage T2D study; shares up 1% premarket</a></h4><ul><li>Novo Nordisk (NYSE:<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://globenewswire.com/news-release/2018/08/20/1553772/0/en/Oral-semaglutide-provides-superior-HbA1c-and-weight-reductions-versus-placebo-in-people-with-type-2-diabetes-and-renal-impairment-in-the-PIONEER-5-trial.html\" target=\"_blank\">announcement</a> of positive results from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02827708\" target=\"_blank\">PIONEER 5</a>, evaluating its oral semaglutide in adults with type 2 diabetes with moderate renal impairment.</li><li>The study met the primary endpoint of a statistically valid reduction in HbA1c compared to placebo at week 26.</li><li>The company says the 10-trial PIONEER program should wind up this year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384109\" data-linked=\"Novo&#39;s oral semaglutide successful in late-stage T2D study; shares up 1% premarket\" data-tweet=\"$NVO - Novo&#39;s oral semaglutide successful in late-stage T2D study; shares up 1% premarket https://seekingalpha.com/news/3384109-novos-oral-semaglutide-successful-in-late-stage-t2d-study-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3384109-novos-oral-semaglutide-successful-in-late-stage-t2d-study-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384097\" data-ts=\"1534769464\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSKN\" target=\"_blank\">SSKN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384097-strata-skin-sciences-inks-xtrac-laser-deal-large-dermatology-group-shares-up-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Strata Skin Sciences inks XTRAC laser deal with large dermatology group; shares up 5% premarket</a></h4><ul><li>Thinly traded nano cap STRATA Skin Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SSKN' title='STRATA Skin Sciences, Inc'>SSKN</a>) is up&nbsp;<font color='green'>5%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/17248626-strata-skin-sciences-announces-strategic-agreement-large-private-equity-backed-group\" target=\"_blank\">announcement </a>that it has entered into a strategic marketing agreement with one an unnamed dermatology group aimed at deploying XTRAC excimer lasers across its network of clinics.</li><li>Each laser, used to treat skin conditions like psoriasis, vitiligo and eczema, will be placed on a pay-per-use basis with no upfront costs to the clinics. The first 10 devices will be deployed before year-end.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384097\" data-linked=\"Strata Skin Sciences inks XTRAC laser deal with large dermatology group; shares up 5% premarket\" data-tweet=\"$SSKN - Strata Skin Sciences inks XTRAC laser deal with large dermatology group; shares up 5% premarket https://seekingalpha.com/news/3384097-strata-skin-sciences-inks-xtrac-laser-deal-large-dermatology-group-shares-up-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3384097-strata-skin-sciences-inks-xtrac-laser-deal-large-dermatology-group-shares-up-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384096\" data-ts=\"1534769235\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCM\" target=\"_blank\">CMCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384096-cheetah-mobile-up-12-premarket-sees-sequential-revenue-growth-resuming\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cheetah Mobile  up 12% premarket, sees sequential revenue growth resuming</a></h4><ul><li>Cheetah Mobile (NYSE:<a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a>)&nbsp;<font color='green'>+12%</font>&nbsp;in premarket trading as Q2 revenue beat consensus and the mobile internet company predicts that quarterly revenue will resume sequential growth trends.</li><li>The company sees Q3 revenue 1.29B yuan (US$194.9M)-1.35B yuan (US$204.0M). Q2 revenue of 1.10B yuan (US$113.7M) beat consensus by $12.7M and exceeded its own guidance of 1.02B yuan-1.08B yuan.</li><li>\"In this quarter, revenues from mobile utility products in the domestic market grew substantially, primarily driven by our Clean Master application for the Chinese market, which reached over 30 million DAUs in June,\" says Chairman and CEO Sheng Fu.</li><li>In H2, the Cheetah mobile sees growth coming from its mobile utility products business in the domestic market, growth in its mobile game business, and normal seasonality effect.</li><li>Q2 adjusted EBITDA rose 30% to 164.2M yuan (US$24.8M) Y/Y.</li><li>Operating margin of 11.6% slipped from 11.9% in Q1.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17248602-cheetah-mobile-announces-second-quarter-2018-unaudited-consolidated-financial-results\" target=\"_blank\">Press Release</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3384077-cheetah-mobile-misses-0_49-beats-revenue\" target=\"_blank\">Cheetah Mobile misses by $0.49, beats on revenue</a> (Aug. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3384096\" data-linked=\"Cheetah Mobile  up 12% premarket, sees sequential revenue growth resuming\" data-tweet=\"$CMCM - Cheetah Mobile up 12% premarket, sees sequential revenue growth resuming https://seekingalpha.com/news/3384096-cheetah-mobile-up-12-premarket-sees-sequential-revenue-growth-resuming?source=tweet\" data-url=\"https://seekingalpha.com/news/3384096-cheetah-mobile-up-12-premarket-sees-sequential-revenue-growth-resuming\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384094\" data-ts=\"1534768926\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSKN\" target=\"_blank\">SSKN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384094-strata-skin-sciences-inks-deal-private-equity-backed-group-of-dermatology-clinics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">STRATA Skin Sciences inks deal with private equity backed group of dermatology clinics</a></h4><ul> <li>STRATA Skin Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SSKN' title='STRATA Skin Sciences, Inc'>SSKN</a>) <a href=\"https://seekingalpha.com/pr/17248626-strata-skin-sciences-announces-strategic-agreement-large-private-equity-backed-group\" target=\"_blank\">signs</a> a strategic marketing agreement with one of the nations&rsquo; largest private equity backed dermatology groups.</li>     <li>The agreement allows for deployment across the group&rsquo;s network of dozens of clinics to place the XTRAC&nbsp;excimer laser and to utilize XTRAC value-add business model. The placement is on a pay per use basis with no upfront cost to the practices.</li>  <li>The agreement will be implemented across the group&rsquo;s network, with the first 10 clinics expected to be deployed before the end of 2018. Financial terms are not disclosed.</li><li>Shares are up&nbsp;<font color='green'>7%</font>&nbsp;premarket.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3384094\" data-linked=\"STRATA Skin Sciences inks deal with private equity backed group of dermatology clinics\" data-tweet=\"$SSKN - STRATA Skin Sciences inks deal with private equity backed group of dermatology clinics https://seekingalpha.com/news/3384094-strata-skin-sciences-inks-deal-private-equity-backed-group-of-dermatology-clinics?source=tweet\" data-url=\"https://seekingalpha.com/news/3384094-strata-skin-sciences-inks-deal-private-equity-backed-group-of-dermatology-clinics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384093\" data-ts=\"1534768788\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSC-OLD\" target=\"_blank\">SSC-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384093-seven-stars-group-skyrockets-after-electric-bus-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seven Stars Group skyrockets after electric bus deal</a></h4><ul> <li>Seven Stars Cloud (NASDAQ:<a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>) skyrockets after <a href=\"https://seekingalpha.com/pr/17248700-seven-stars-cloud-signs-exclusive-ground-breaking-three-year-24b-deal-chinas-largest-electric\" target=\"_blank\">signing</a> an exclusive $24B three-year deal with China's largest electric bus full-service operator.</li> <li>The company says it will conduct financing activities through the sale of fixed income products to raise ~$8.75B over three years to fund the electric bus production blitz.</li> <li>Seven Stars is&nbsp;<font color='green'>up 148%</font> to $4.89 on premarket action of over 150K shares. The 52-week high on SSC is $7.00.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3384093\" data-linked=\"Seven Stars Group skyrockets after electric bus deal\" data-tweet=\"$SSC-OLD - Seven Stars Group skyrockets after electric bus deal https://seekingalpha.com/news/3384093-seven-stars-group-skyrockets-after-electric-bus-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3384093-seven-stars-group-skyrockets-after-electric-bus-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>47&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384092\" data-ts=\"1534768778\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBPO\" target=\"_blank\">CBPO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384092-china-biologic-up-18-premarket-on-118-share-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Biologic up 18% premarket on $118/share bid</a></h4><ul><li>China Biologic Products Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CBPO' title='China Biologic Products, Inc.'>CBPO</a>) is up&nbsp;<font color='green'>18%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17248730-leading-investor-group-proposes-acquire-china-biologic-products-us-118_00-per-share-cash\" target=\"_blank\">announcement </a>that an investment group has made a non-binding proposal to acquire all the remaining shares of the company that it does not already own at $118 in cash. The total transaction value will be ~$3.9B.</li><li>Goldman Sachs is advising.</li><li><strong>Update</strong>: On Tuesday, August 21, the company <a href=\"https://seekingalpha.com/pr/17249745-china-biologic-announces-receipt-competing-non-binding-acquisition-proposal\" target=\"_blank\">announced </a>that it received the non-binding proposal.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384092\" data-linked=\"China Biologic up 18% premarket on $118/share bid\" data-tweet=\"$CBPO - China Biologic up 18% premarket on $118/share bid https://seekingalpha.com/news/3384092-china-biologic-up-18-premarket-on-118-share-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3384092-china-biologic-up-18-premarket-on-118-share-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384088\" data-ts=\"1534768375\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AQST\" target=\"_blank\">AQST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384088-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Aquestive Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AQST' title='Aquestive Therapeutics'>AQST</a>) initiated with Outperform rating and $29 (81% upside) price target at JMP Securities. Initiated with Outperform rating and $26 price target at BMO Capital Markets.</li><li>The Medicines Company (NASDAQ:<a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a>) price target raised to $50 (25% upside) from $40 at Citigroup. Buy rating maintained.</li><li>Bayer AG (<a href='https://seekingalpha.com/symbol/BAYRY' title='Bayer A.G. ADR'>OTCPK:BAYRY</a>) resumed with Outperform rating at Credit Suisse.</li><li>Addus Homecare (NASDAQ:<a href='https://seekingalpha.com/symbol/ADUS' title='Addus HomeCare Corporation'>ADUS</a>) initiated with Outperform rating and $75 (20% upside) price target at Raymond James.</li><li>Liquidia Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/LQDA' title='Liquidia Technologies'>LQDA</a>) initiated with Outperform rating and $40 (167% upside) price target at Cowen and Company. Initiated with Buy rating and $30 price target at Needham. Initiated with Buy rating and $22 price target at Jefferies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384088\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$AQST $AQST $MDCO - Premarket analyst action - healthcare https://seekingalpha.com/news/3384088-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3384088-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384079\" data-ts=\"1534767274\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YOGA\" target=\"_blank\">YOGA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384079-yogaworks-lower-after-cowen-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">YogaWorks lower after Cowen cut</a></h4><ul> <li>YogaWorks (NASDAQ:<a href='https://seekingalpha.com/symbol/YOGA' title='YogaWorks'>YOGA</a>) slides in early trading after Cowen <a href=\"https://www.marketwatch.com/story/yogaworks-shares-slide-after-downgrade-on-potential-revenue-decline-2018-08-20?mod=newsviewer_click\" target=\"_blank\">downgrades</a> the stock to a Market Perform rating from Outperform on near-term concerns.</li> <li>\"We do believe YogaWorks is making the right decisions for the long-term health of the business and customer lifetime value, but the stock valuation could be sideways as the company undergoes needed change,\" writes analyst Oliver Chen and team.</li> <li>Cowen pulled its prior target of $7 as it takes a breather.</li> <li>Shares of YogaWorks are <font color='red'>down 1.69%</font> in premarket trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384079\" data-linked=\"YogaWorks lower after Cowen cut\" data-tweet=\"$YOGA - YogaWorks lower after Cowen cut https://seekingalpha.com/news/3384079-yogaworks-lower-after-cowen-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3384079-yogaworks-lower-after-cowen-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384078\" data-ts=\"1534767129\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PPDF\" target=\"_blank\">PPDF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384078-china-re-checking-p2p-lenders-bloomberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China re-checking P2P lenders - Bloomberg</a></h4><ul><li>According to a document seen by Bloomberg, Chinese regulators continue to try and clean up the wild west business of P2P lending by - among other things - pushing for some to exit the industry.</li><li>That news is sending established players like PPDAI Group (NYSE:<a href='https://seekingalpha.com/symbol/PPDF' title='PPDAI Group Inc.'>PPDF</a>) and Yirendai (NYSE:<a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a>) higher premarket by&nbsp;<font color='green'>5.15% and 4.75%</font>, respectively.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384078\" data-linked=\"China re-checking P2P lenders - Bloomberg\" data-tweet=\"$PPDF $FINV $YRD - China re-checking P2P lenders - Bloomberg https://seekingalpha.com/news/3384078-china-re-checking-p2p-lenders-bloomberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3384078-china-re-checking-p2p-lenders-bloomberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384077\" data-ts=\"1534766891\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCM\" target=\"_blank\">CMCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384077-cheetah-mobile-misses-0_49-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cheetah Mobile misses by $0.49, beats on revenue</a></h4><ul><li>Cheetah Mobile (NYSE:<a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a>): Q2 Non-GAAP ADS of $0.21 misses by $0.49; GAAP ADS of $0.19 misses by $0.26.</li><li>Revenue of $166.8M (-8.1% Y/Y) <font color='green'>beats by $12.73M</font>.</li><li>Shares <font color='green'>+15%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17248602-cheetah-mobile-announces-second-quarter-2018-unaudited-consolidated-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3384077\" data-linked=\"Cheetah Mobile misses by $0.49, beats on revenue\" data-tweet=\"$CMCM - Cheetah Mobile misses by $0.49, beats on revenue https://seekingalpha.com/news/3384077-cheetah-mobile-misses-0_49-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3384077-cheetah-mobile-misses-0_49-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384071\" data-ts=\"1534766382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AU\" target=\"_blank\">AU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384071-anglogoldplus-2-full-year-output-seen-top-costs-low-end-of-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AngloGold +2% as full-year output seen at top, costs at low end of guidance</a></h4><ul>     <li>AngloGold Ashanti (NYSE:<a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a>) <font color='green'>+2.2%</font> pre-market after swinging to a net <a href=\"https://seekingalpha.com/news/3384033-anglogold-ashanti-reports-1h-results\" target=\"_blank\">H1 profit</a> and forecasting FY 2018 production at the top end and costs at the bottom end of company guidance.</li>     <li>AU says it expects to meet the top end of its full-year production outlook of 3.3M-3.5M oz. of gold, while all-in sustaining costs are seen at the low end of guidance of $990-$1,060/oz.</li>     <li>For H1, total revenue slipped 5% Y/Y to $1.92B, net debt fell 17% to $1.79B, total production slid 6% to 1.63M gold oz. and all-in sustaining costs fell 5% to $1,020/oz.</li>     <li>&ldquo;<a href=\"https://finance.yahoo.com/news/anglogold-swings-profit-costs-drop-053225902.html\" target=\"_blank\">The business is in good shape</a>,&rdquo; says CEO Srinivasan Venkatakrishnan, who will leave the company at the end of August when Barrick Gold&rsquo;s Kelvin Dushnisky takes the helm. &ldquo;Production is strong, costs are improving and our pipeline is well stocked with options.&rdquo;</li>     <li>AU began preparations to redevelop its idled Obuasi mine in Ghana after receiving government approvals, an accomplishment the CEO says ranks among his \"most satisfying\"as he prepares to step down.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384071\" data-linked=\"AngloGold +2% as full-year output seen at top, costs at low end of guidance\" data-tweet=\"$AU - AngloGold +2% as full-year output seen at top, costs at low end of guidance https://seekingalpha.com/news/3384071-anglogoldplus-2-full-year-output-seen-top-costs-low-end-of-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3384071-anglogoldplus-2-full-year-output-seen-top-costs-low-end-of-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384070\" data-ts=\"1534766355\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384070-nike-catches-pair-of-upgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike catches pair of upgrades</a></h4><ul> <li>Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a>) is on watch after catching two upgrades from the Wall Street crowed.</li> <li>Piper Jaffray bumps Nike up to Overweight from Neutral on its view that the athletic category will continue to grow, led by a reacceleration in North America. E-commerce is still seen as a significant tailwind to Nike's business.</li> <li>Susquehanna lifts Nike to Positive from Neutral, noting that the Swoosh is grabbing market share back from Adidas. Analyst Sam Poser and team are confident that Nike will hits its FY23 $50B revenue target.</li> <li>Shares of Nike are <font color='green'>up 2.02%</font> in premarket trading to $81.36.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384070\" data-linked=\"Nike catches pair of upgrades\" data-tweet=\"$NKE - Nike catches pair of upgrades https://seekingalpha.com/news/3384070-nike-catches-pair-of-upgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3384070-nike-catches-pair-of-upgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384067\" data-ts=\"1534766044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384067-nike-scores-couple-of-upgrades-shares-gain-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike scores a couple of upgrades; shares gain 2% premarket</a></h4><ul><li>The e-commerce boom is \"a significant tailwind\" for athletic brands, given low Amazon risk, says Piper's Erinn Murphy, upgrading Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a>) to Overweight from Neutral. Her $93 price target suggests more than&nbsp;<font color='green'>15% upside</font>.</li><li>\"Improvements in North American wholesale\" are evident, says Susquehanna's Sam Poser, upgrading to Positive from Neutral, and also with $93 price target. Nike, he says, is gaining share from Adidas, as well as retailers like Foot Locker, Finish Line, and Hibbett.</li><li>Source: Bloomberg</li><li>Shares&nbsp;<font color='green'>+2.2%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3384067\" data-linked=\"Nike scores a couple of upgrades; shares gain 2% premarket\" data-tweet=\"$NKE - Nike scores a couple of upgrades; shares gain 2% premarket https://seekingalpha.com/news/3384067-nike-scores-couple-of-upgrades-shares-gain-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3384067-nike-scores-couple-of-upgrades-shares-gain-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384065\" data-ts=\"1534765798\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOVN\" target=\"_blank\">NOVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384065-novan-up-22-premarket-on-encouraging-performance-of-sb414-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novan up 22% premarket on encouraging performance of SB414 2%</a></h4><ul><li>Thinly traded nano cap Novan (NASDAQ:<a href='https://seekingalpha.com/symbol/NOVN' title='Novan'>NOVN</a>) is up&nbsp;<font color='green'>22%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17248516-novan-announces-promising-clinical-results-sb414\" target=\"_blank\">announcement</a> of positive early-stage data on topical cream SB414.</li><li>A recently completed Phase 1b trial in atopic dermatitis &#40;AD&#41; showed the a topical nitric oxide therapeutic has efficacy potential. The company says clinical results and biomarker data support advancing nitric oxide-based treatments for a range of inflammatory skin diseases including AD, psoriasis and acne rosacea.</li><li>Results from the Phase 1b trial in 48 adults with mild-to-moderate AD showed that treatment with SB414 2% cream downregulated pro-inflammatory cytokines, producing statistically significant reductions compared to vehicle (placebo). The proportion of patients achieving at least a three-point improvement in an itching scale after two weeks of treatment was 71% in the treatment group versus 43% for vehicle.</li><li>The results for the 6% formulation of SB414 failed to demonstrate a treatment benefit. It was not consistently effective in reducing biomarkers across the AD and psoriasis studies, possibly due to increased irritation scores. Systemic exposure was detected in a subset of participants (unwanted) which cleared in almost all within 12 hours.</li><li>It intends to advance SB414 2% in AD and conduct exploratory studies in psoriasis and acne rosacea.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384065\" data-linked=\"Novan up 22% premarket on encouraging performance of SB414 2%\" data-tweet=\"$NOVN - Novan up 22% premarket on encouraging performance of SB414 2% https://seekingalpha.com/news/3384065-novan-up-22-premarket-on-encouraging-performance-of-sb414-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3384065-novan-up-22-premarket-on-encouraging-performance-of-sb414-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384055\" data-ts=\"1534764258\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EL\" target=\"_blank\">EL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384055-estee-lauder-lower-after-guidance-falls-short\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Estee Lauder lower after guidance falls short</a></h4><ul> <li>Estee Lauder (NYSE:<a href='https://seekingalpha.com/symbol/EL' title='Estee Lauder Companies, Inc. &#40;The&#41;'>EL</a>) tops estimates with its FQ4 report as sales rose in almost every category.</li> <li>Sales increased 12% during the quarter after the impact of currency swings is factored out. Skin care sales were up 29% and fragrance sales increased 9%.</li> <li>Operating income was up 20% Y/Y to $277M.</li> <li>Looking ahead, Estee Lauder expects Q1 revenue growth of 5% to 6% and EPS of $1.18 to $1.22 vs. $1.32 and FY19 revenue growth of 4% to 5% and FY19 EPS of $4.62 to $4.71 vs. $5.00 consensus.</li> <li>Shares of Estee Lauder are <font color='red'>down 2.17%</font> in premarket trading to $133.00.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3384040-estee-lauder-beats-0_05-beats-revenue\" target=\"_blank\">Estee Lauder beats by $0.05, beats on revenue</a> (Aug. 20)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3384055\" data-linked=\"Estee Lauder lower after guidance falls short\" data-tweet=\"$EL - Estee Lauder lower after guidance falls short https://seekingalpha.com/news/3384055-estee-lauder-lower-after-guidance-falls-short?source=tweet\" data-url=\"https://seekingalpha.com/news/3384055-estee-lauder-lower-after-guidance-falls-short\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384050\" data-ts=\"1534763619\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LCI\" target=\"_blank\">LCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384050-jerome-stevens-nixes-distribution-deal-lannett-shares-down-26-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jerome Stevens nixes distribution deal with Lannett; shares down 26% premarket</a></h4><ul><li>Jerome Stevens Pharmaceuticals &#40;JSP&#41; has <a href=\"https://seekingalpha.com/pr/17248531-lannett-provides-update-contract-renewal-jerome-stevens-pharmaceuticals\" target=\"_blank\">notified </a>Lannett Company (NYSEMKT:<a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc'>LCI</a>) that their distribution agreement three JSP products, Butalbital, Aspirin, Caffeine with Codeine Phosphate Capsules ASP, Digoxin Tablets USP and Levothyroxine Sodium Tablets USP, will not be renewed when the current agreement expires on March 23, 2019.</li><li>Lannett says it is assessing the impact to the end of contract on its goodwill. It is also evaluating additional deals to add to its portfolio.</li><li>Preliminary fiscal Q4 sales: ~$171M (+23%) with a loss/share of ($0.30 - 0.32). Non-GAAP EPS should be $0.62 - 0.64 (+58% from midpoint).</li><li>Fiscal 2018: Sales: ~$685M (+7%); EPS: $0.73 - 0.75; non-GAAP EPS: $3.08 - 3.10 (+8% from midpoint).</li><li>Full results will be reported on August 28 after the close.</li><li><strong>Update</strong>: Shares are down&nbsp;<font color='red'>26%</font>&nbsp;premarket on light volume.</li><li><strong>Update</strong>: Jerome Stevens inked a <a href=\"https://seekingalpha.com/pr/17248585-amneal-announces-10-year-licensing-supply-agreement-jerome-stevens-pharmaceuticals-inc\" target=\"_blank\">10-year distribution deal</a> with Amneal Pharmaceuticals for Levothyroxine sodium beginning March 22, 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384050\" data-linked=\"Jerome Stevens nixes distribution deal with Lannett; shares down 26% premarket\" data-tweet=\"$LCI - Jerome Stevens nixes distribution deal with Lannett; shares down 26% premarket https://seekingalpha.com/news/3384050-jerome-stevens-nixes-distribution-deal-lannett-shares-down-26-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3384050-jerome-stevens-nixes-distribution-deal-lannett-shares-down-26-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3384049\" data-ts=\"1534763534\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESLT\" target=\"_blank\">ESLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3384049-elbitplus-3-after-imi-regulatory-approval\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Elbit +3% after IMI regulatory approval</a></h4><ul><li>Elbit Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/ESLT' title='Elbit Systems Ltd.'>ESLT</a>) <font color='green'>+3%</font> premarket after Israel's antitrust regulator <a href=\"https://www.reuters.com/article/elbit-systems-ma-imi/israel-regulator-okays-defence-firm-elbits-bid-to-buy-imi-idUSL8N1VA07F?feedType=RSS&amp;feedName=companyNews\" target=\"_blank\">approved</a> the defense contractor's planned acquisition of state-owned rival IMI Systems for up to $522M.</li><li>\"In particular, it was found that the overlap between the activities of Elbit and IMI is relatively marginal, and that in the overlapping areas there is competition from suppliers in Israel or abroad.\"</li><li>The Israeli government announced in 2013 its intention to privatize IMI, a manufacturer of military systems best known for being an early maker of the Uzi submachine gun.</li></ul><div class=\"tiny-share-widget\" data-id=\"3384049\" data-linked=\"Elbit +3% after IMI regulatory approval\" data-tweet=\"$ESLT - Elbit +3% after IMI regulatory approval https://seekingalpha.com/news/3384049-elbitplus-3-after-imi-regulatory-approval?source=tweet\" data-url=\"https://seekingalpha.com/news/3384049-elbitplus-3-after-imi-regulatory-approval\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:12 AM </div></div></li>","count":70,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}